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Summary  
 
Chronic obstructive pulmonary disease (COPD) is characterized by an irreversible loss of 
lung function and is one of the most prevalent and severe diseases world-wide. A major 
feature of COPD is emphysema- a long-term, progressive condition. The hallmark of 
emphysema includes the destruction of alveolar structures leading to enlarged air spaces 
and reduced surface area. Experimental evidence suggests that emphysema development is 
driven by accelerated senescence of lung cells but the underlying mechanism of senescence 
is yet to be fully elucidated. 
  
Protein arginine methyltransferases (PRMTs) are important for cellular processes, such as 
the regulation of senescence, cell proliferation, differentiation and apoptosis. The PRMT 
family includes 11 members classified as type I, II or III enzymes depending on their 
methylation pattern (asymmetric dimethylation, symmetric dimethylation or monomethylation, 
respectively). One member of this family is PRMT4, a type I enzyme, which is also called 
coactivator associated arginine methyltransferase 1 (CARM1). It was originally identified as a 
coactivator for steroid hormone receptors. CARM1 is known to methylate histone H3 and 
various non-histone proteins that play essential roles in transcriptional regulation, RNA 
splicing, and metabolism. Most importantly, complete loss of CARM1 leads to disrupted 
differentiation and maturation of alveolar epithelial type-II cells (ATII). Furthermore, CARM1 
also plays a role in regulating cellular senescence via CARM1-dependent methylation.  
 
Based on these reports, we hypothesized that CARM1 regulates the development and 
progression of emphysema. To address this, we investigated the contribution of CARM1 to 
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alveolar rarefication using the mouse model of elastase-induced emphysema in vivo and 
siRNA-mediated knockdown in ATII-like LA4 cells in vitro. 
 
In vivo experiments:  
We monitored emphysema progression for 161 days in mice treated with a single 
oropharyngeal application of elastase. The progression was manifested by the decline in 
lung function parameters. The mean chord length (Lm) confirmed a time dependent airspace 
enlargement and was directly correlated with a significant increase in dynamic lung 
compliance. We also observed that at later time points (day 56 and 161), emphysema 
progression was inflammation-independent. We demonstrated that emphysema 
advancement was associated with a time-dependent downregulation of CARM1, specifically 
in alveolar epithelial cells. Furthermore, the global CARM1 activity was also reduced as 
reflected by an elevated level of CARM1 phosphorylation in the lung. Most importantly, 
elastase-treated CARM1 haploinsufficient mice showed significantly increased airspace 
enlargement (52.5±9.6 µm vs. 38.8±5.5 µm, p<0.01) and lung compliance (2.8±0.32 
µl/cmH20 vs. 2.4±0.4 µl/cmH20, p<0.04) compared with wild type controls. Reduced CARM1 
contributed to senescence of alveolar epithelial cells evident by the reduction of anti-
senescence SIRT1 and the induction of senescence markers p16 and β-galactosidase in 
alveolar epithelial cells. We further demonstrated that CARM1 haploinsufficiency impaired 
trans-differentiation of ATII into ATI cells. Elastase treatment in CARM1 deficient mouse 
lungs led to the accumulation of SP-C positive ATII cell.  
 
In vitro experiment: 
In our in vitro studies, we detected that the knockdown of CARM1 in the ATII-like cell line LA-
4 led to decreased SIRT1 expression (0.034±0.003 vs. 0.022±0.001, p<0.05), but increased 
expression of p16 (0.27±0.013 vs. 0.31±0.010, p<0.5), p21 (0.81±0.088 vs. 1.28± 0.063, 
p<0.01) and induced a higher number of β-galactosidase-positive senescent cells 
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(50.57%±7.36 vs. 2.21%±0.34, p<0.001), compared with scrambled siRNA. The senescence 
in CARM1 deficient cells was further augmented after CSE stimulation. Furthermore, we 
demonstrated that CARM1 deficiency impaired wound healing (32.18%±0.9512 vs. 
8.769%±1.967 wound gap closure, p<0.001) of alveolar epithelial cells. The data confirmed 
that CARM1 reduction induced an accelerated senescence in LA-4 cells by attenuating the 
effect of SIRT1.  
 
Overall, both our in vivo and in vitro results revealed a novel function of CARM1 in regulating 
emphysema development and premature lung aging via alveolar senescence, as well as 
impaired regeneration, repair and differentiation of ATII cells.  
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Zusammenfassung 
 
Die chronisch obstruktive Lungenerkrankung (COPD) zählt zu den häufigsten schweren 
Krankheiten weltweit und ist gekennzeichnet durch eine irreversible Abnahme der 
Lungenfunktion. Ein Hauptcharakteristikum von COPD ist das Emphysem, das sich stetig 
über einen langen Zeitraum fortschreitend entwickelt, und durch die Zerstörung alveolärer 
Strukturen, einhergehend mit vergrößerten Lufträumen und verringerter Alveolaroberfläche, 
gekennzeichnet ist. Ergebnisse aus Studien legen nahe, dass die Entwicklung des 
Emphysems durch die erhöhte Seneszenz von Zellen der Lunge beschleunigt wird, doch die 
genauen zugrundeliegenden Mechanismen sind noch nicht aufgeklärt. 
 
Protein-Arginin-Methyltransferasen (PRMTs) spielen eine bedeutende Rolle bei zellulären 
Prozessen wie Regulation von Seneszenz, Zellproliferation, Differenzierung und Apoptose. 
Die Familie der PRMTs umfasst 11 Enzyme, die als Typ I, II, oder III klassifiziert werden, 
abhängig von ihrem Methylierungsmuster (asymmetrische Dimethylierung, symmetrische 
Dimethylierung oder Monomethylierung). Ein Mitglied der Familie ist PRMT4, ein Typ I 
Enzym, das auch unter dem Namen Coactivator-assoziierte Arginin-Methyltransferase 1 
(CARM1) bekannt ist. Ursprünglich wurde CARM1 als Coactivator für Steroid-Hormon-
Rezeptoren beschrieben. CARM1 methyliert Histon 3 und verschiedene weitere Nicht-Histon 
Proteine, die eine wichtige Rolle für die Transkriptionsregulation, das RNA-Splicing und den 
Stoffwechsel spielen. Darüberhinaus führt der komplette Verlust von CARM1 zu gestörter 
Differenzierung und Maturation von Typ II Alveolarepithelzellen (ATII). Weiterhin ist CARM1 
von Bedeutung für die Regulation von zellulärer Seneszenz mittels CARM1-abhängiger 
Methylierung. 
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Auf Grundlage dieser Arbeiten wurde die Hypothese aufgestellt, dass CARM1 die 
Entwicklung und das Voranschreiten des Emphysems reguliert. Um dies aufzuklären, wurde 
die Rolle von CARM1 am Verlust der Alveolen in einem Elastase-induzierten Emphysem-
Mausmodell in vivo sowie in vitro mittels siRNA knockdown in ATII-ähnlichen LA4-Zellen 
untersucht. 
 
In vivo Experimente: 
Die Entwicklung und das Voranschreiten des Emphysems wurden über einen Zeitraum von 
161 Tagen beobachtet. Dabei zeigte sich eine progressive Abnahme verschiedener 
Lungenfunktionsparameter. Die mittlere Alveolarweite bestätigte die zeitabhängige 
Vergrößerung des Luftraumes und war direkt mit einer signifikanten Zunahme der 
dynamischen Lungencompliance korreliert. Außerdem wurde an späteren Zeitpunkten (Tag 
56 und 161) eine entzündungsabhängige Progression des Emphysems beobachtet. Das 
Voranschreiten des Emphysems war mit einer zeitabhängigen Herunterregulierung von 
CARM1 insbesondere in Alveolarepithelzellen assoziiert. Die Gesamtaktivität von CARM1 
war ebenso reduziert, erkennbar anhand von erhöhter CARM1-Phosphorylierung in der 
Lunge. Weiterhin zeigten mit Elastase behandelte CARM1 haploinsuffiziente Mäuse eine 
signifikant erhöhte Vergrößerung des Luftraumes (52.5±9.6 µm vs. 38.8±5.5 µm, p<0.01) 
sowie der Lungencompliance (2.8±0.32 µl/cmH20 vs. 2.4±0.4 µl/cmH20, p<0.04) verglichen 
mit Wildtyp-Kontrollmäusen. Das verringerte Level an CARM1 trug zur Seneszenz von 
Alveolarepithelzellen bei, bestätigt durch eine Reduktion des Anti-Seneszenz-Markers SIRT1 
und durch die Induktion der Seneszenz-Marker p16 und β-Galactosidase in 
Alveolarepithelzellen. Des Weiteren wurde gezeigt, dass CARM1 Haploinsuffizienz die 
Transdifferenzierung von ATII zu ATI Zellen verhindert. Dabei führte die Elastase-
Behandlung von CARM1-defizienten Mäusen zu einer Akkumulation von SP-C-positiven 
ATII-Zellen in der Lunge.    
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In vitro Experimente: 
Die in vitro Experimente haben gezeigt, dass der knockdown von CARM1 in ATII-ähnlichen 
LA4-Zellen zu einer verringerten SIRT1-Expression (0.034±0.003 vs. 0.022±0.001, p<0.05), 
und gleichzeitig zu einer erhöhten Expression von p16 (0.27±0.013 vs. 0.31±0.010, p<0.5), 
p21 (0.81±0.088 vs. 1.28± 0.063, p<0.01) führte. Weiterhin verursachte der CARM1 
knockdown eine erhöhte Anzahl an β-Galactosidase-positiven seneszenten Zellen verglichen 
mit Kontroll-siRNA-behandelten Zellen (50.57%±7.36 vs. 2.21%±0.34, p<0.001). Die erhöhte 
Seneszenz in CARM1-defizienten Zellen wurde durch Stimulation mit Zigarettenrauchextrakt 
noch verstärkt. Weiterhin zeigte sich in den Alveolarepithelzellen eine verhinderte 
Wundheilung aufgrund CARM1-Defizienz (32.18%±0.9512 vs. 8.769%±1.967 
Wundschließung, p<0.001). Diese Daten bestätigten, dass die Reduzierung von CARM1 
eine beschleunigte Seneszenz in LA4-Zellen mittels Abschwächung von SIRT1-Effekten 
verursachte. 
 
Zusammenfassend zeigen die in vivo und vitro Ergebnisse eine neue Rolle von CARM1 bei 
der Regulierung der Emphysem-Entstehung und der vorzeitigen Lungenalterung, in erster 
Linie mittels Seneszenz von Alveolarepithelzellen, sowie beeinträchtigter Regenerierung, 
Reparatur und Differenzierung von ATII-Zellen.  
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1. INTRODUCTION 
 
1.1 Chronic obstructive pulmonary disease  
Chronic obstructive pulmonary disease (COPD) is a life-threatening lung disease worldwide. 
According to the World Health Organization (WHO), COPD will stand as the third leading 
cause of death worldwide by the year 2030 (1). The mortality rate of COPD will continue to 
rise in near future because of a rapidly increasing aging population worldwide. More than 5% 
of the population over the age of 40 is now affected with COPD (2). It is a major global health 
problem which is associated with high health-care cost. A stage III COPD patient has an 
approximate health care cost of $10,812 per year (3). The staggering socioeconomic burden 
that comes with COPD treatment and management is currently surpassing any other disease 
and thus triggers interest in scientific community to better understand the disease (4).  
 
COPD refers to an obstructive disease of lungs manifesting a slow, gradual progression over 
decades that ultimately leads to mortality from respiratory failure (5).The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), collaboration between the National Institutes of 
Health and the World Health Organization states a standard definition of COPD. According to 
GOLD COPD is a disease characterized by airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lung to 
noxious particles or gases. Exacerbations and comorbidities contribute to severity of the 
disease (6). The airflow limitation is the outcome of an increased small conducting airway 
resistance and an increased lung compliance due to emphysematous destruction (7). The 
common symptoms that arise in a COPD patient are usually chronic and progressive 
shortness of breath (dyspnea), chronic cough and sputum production (8). Pathologically, all 
these symptoms are the outcome of an airflow limitation. COPD is not just a single disease, 
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rather a group of conditions that includes chronic bronchitis, small airway remodeling and 
emphysema. All these three conditions can exist in patients separately or in combination. 
 
Chronic bronchitis 
The major features of chronic bronchitis are excessive mucus production and chronic 
infiltration of inflammatory cell at the bronchial wall (9). The pathological changes that cause 
increased mucus production include goblet cell hyperplasia and submucosal gland 
hypertrophy associated with loss of ciliated cells. As an outcome, there is reduced 
mucociliary clearance and increase mucus plug formation (10). If the occurrence of the 
mucus secretion persists three months a year, for at least two consecutive years without any 
other pulmonary cause, then it has to be considered as chronic bronchitis (11). As a 
physiological symptom, the COPD patient suffers from a chronic cough. 
 
Small airway remodeling  
The peripheral airways of 2 millimeters or less in diameter is the major site of remodeling 
(12). In smokers, these airways become even smaller with a diameter less than 0.4 
millimeters (13). Airway remodeling is an outcome of the inflammatory response associated 
with COPD (14). In addition to inflammation, other factors that contribute to airway 
remodeling are metaplasia of goblet cells and peribronchial fibrosis leading to a thickening of 
airway walls which narrows the lumen and as a consequence, there is a marked increase in 
resistance to airflow in the small airways (15, 16).  
 
Emphysema 
The hallmark of emphysema is the destruction of alveolar structures leading to enlarged air 
spaces and reduced surface area (Figure 1) (17). As the focus of this dissertation is 
emphysema, a detailed overview is discussed in next section.  
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Figure 1. Pulmonary emphysema. Emphysema is a progressive lung disease affecting alveolar sacs, alveoli and disrupts 
gas exchange capacity leading to less oxygen entrance into the bloodstream. Loss of alveolar elastic recoiling cause them to 
collapse and trap air every time the patient expels air. Adapted and modified from www.oxygenconcentratordepot.com. 
 
1.2 Pulmonary emphysema: Pathological definition 
In lung, respiratory unit is the site where emphysema occurs. It is slowly progressive disease 
described as a loss of lung elasticity and abnormal enlargement of the air spaces distal to the 
terminal bronchioles, with destruction of the alveolar walls and capillary beds without obvious 
fibrosis (18, 19). Previously, pulmonary emphysema used to be considered due to the 
atrophy of lung tissue resulting from over-inflation (20). Later it was demonstrated that 
indeed, destruction of the lung parenchyma results in loss of gas exchange area in lung and 
decrease of elastic recoiling that leads to lung hyperinflation (21). The destruction of the 
elastic fibers that provide the natural recoil of the lung is actually the early event of 
emphysema that causes deformation of the alveoli and respiratory bronchioles (22, 23). This 
leads to a decreased number of functional alveoli and results in shortness of breath 
(Dyspnea). It is often a strong indicator of emphysema and the most common symptom 
emphysema patients suffer from (24). Emphysema exists in two subtypes. One is centri-
acinar emphysema confined to the apical regions of the lung and characterized by 
destruction of the central zone of the acinus leading to enlarged respiratory bronchioles. 
Another subtype is pan-acinar emphysema involved in an uniform destruction of the whole 
lung acinus and mostly affects the lower lobes of the lung rather than the upper lobes (25). 
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1.2.1 Historical background 
Record of human emphysema was stated back in 1679, when Bonet described of 
voluminous lungs (26). Later in 1721, the Dutch anatomist, Frederick Ruysch observed 
expanded air spaces in lung specimens of humans (27). In 1769, Morgagni recorded 19 
patient cases where the lungs were turgid or inflated with air (28). However, it was between 
1799 and 1807, when Matthew Baillie first pointed out the destructive nature of emphysema 
and illustrated emphysema as enlarged air spaces (29, 30). In 19th century, a French 
physician Laënnec noted that there significant variations in the size of air vesicles in lungs 
ranging from the size smaller than a millet seed to as big as a cherry stone. He hypothesized 
that the bigger, cherry stone size air vesicles were produced by the collapse of adjacent air 
spaces following rupture of alveolar walls (31). In 1892, Osler characterized emphysema as 
enlargement of the lungs due to expansion of the air “cells”, atrophy of their walls and 
imperfect aeration of the blood resulting in dyspnea (32). In 1956, McLean marked 
emphysema as a chronic destructive lung disease noting that there is an enlargement of 
existing airspaces in the lung parenchyma (33). In 1960s, both the World Health 
Organization (WHO) and the American Thoracic Society (ATS) defined emphysema as 
destruction of respiratory tissue manifested by a permanent enlargement of airspaces distal 
to the terminal non-respiratory bronchiole (34, 35). 
 
1.2.2 Risk factors of emphysema 
Emphysema is primarily caused by cigarette smoke, air pollution, environmental factors, 
aging as well as epigenetic modification. 
 
Smoking: Cigarette smoke is considered as the most widely accepted causative factor for 
emphysema (6). Smoking causes approximately 80 to 90 percent of COPD deaths (36). 
Compared to the non-smokers, the smokers experience a substantially significant annual 
decline in FEV1 and rate of mortality (37). Women are even more susceptible to smoking as 
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studies showed that smoking during pregnancy can potentially affect lung growth of the fetus 
by dysregulating the immune system (38). Besides active smoking, the passives exposure, 
also known as second-hand smoking or environmental tobacco smoke can increase the 
burden of inhaled noxious particles and gasses and thus can also contribute in emphysema 
development in 20% of cases of non-smokers (39-41). Other forms of smoking such as pipe, 
cigar, and marijuana also pose as risk factor for emphysema (42-45).  
 
Others: Occupational exposure to dust and chemical fumes are a major risk of COPD for 
both smokers and nonsmokers (46). In the developing countries, exposure to biomass fuel 
for cooking also believed to be a strong etiologic agent of emphysema (47). In addition, 
genetics is likely to play a role. An inherited deficiency of Alpha-1 antitrypsin, a protein that 
protects the elastic tissue in the lungs contributes in the development and progression of the 
emphysema (6, 48).   
 
1.2.3 Diagnosis of emphysema 
In 1846 the spirometer invented by John Hutchinson was the key diagnostic tool for COPD 
(49). The spirometry is the measurement of air moving in and out of lungs during different 
respiratory maneuvers and thus allows to determine how much air can be inhaled or exhaled 
and how fast (50). The pulmonary function testing (PFTs) using spirometer is still used today 
for diagnosis and regular assessment of COPD. However, Hutchinson’s instrument only 
measured vital capacity. The measurable parameters expanded when Tiffeneau and Pinelli 
added the concept of timed vital capacity as a measure of airflow (51). The airflow 
obstruction is defined by spirometric criteria, as a ratio of FEV1/FVC less than 0.7 in the 
absence of other respiratory symptoms where FEV1 is the Forced Expiratory Volume in 1 
second and FVC is the Forced Vital Capacity (52). The classification of severity of COPD, as 
issued by GOLD, is based upon the FEV1/FVC (6) (Table 1).  
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Other pulmonary function test tool includes body plethysmography that measures residual 
volume (RV) to assess changes in lung hyperinflation. Body plethysmography is a routine 
measurement in clinical pulmonary practice based on Boyle’s law, with reproducible 
measurements of absolute lung volumes (53). Other commonly used tests include X-rays or 
computed tomography (CT) scans of the chest to diagnose specific morphologic changes in 
the lung parenchyma (54). Another diagnostic tool oximetry or the diffusing capacity for 
carbon monoxide (DLCO) is a measure of the ability of gas to transfer from the alveoli across 
the alveolar epithelium and the capillary endothelium to the RBCs (55). 
 
Stage of COPD COPD Severity  FEV1 %  
Stage I Mild ≥80 
Stage II Moderate 50–79 
Stage III Severe 30–49 
Stage IV Very severe <30 or chronic respiratory failure 
   
Table 1: GOLD classification in patient with FEV1/FVC <0.70. Adapted from reference (6). 
 
1.2.4 Current treatment for emphysema 
Current available treatments only aim to relieve symptoms and prevent further  emphysema 
progression. Besides treatments, quitting smoking is also essential for patients with 
emphysema, since continuing to use tobacco will only further damage the lungs. Inhaled as 
aerosol sprays or taken orally, bronchodilator medications may help to relieve symptoms of 
emphysema by relaxing and opening the air passages in the lungs. Current bronchodilators 
include β-Agonists, anticholinergics (short-acting ipratropium bromide and long-acting 
tiotropium) and phosphodiesterase inhibitor (theophylline, roflumilast) (56). Corticosteroid 
drugs inhaled as aerosol sprays relieves shortness of breath (57). However, prolonged use 
may weaken bones and increase risk of high blood pressure, cataracts and diabetes (58). 
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Antibiotics such as erythromycin may be used to help fight respiratory infections common in 
people with emphysema, such as acute bronchitis, pneumonia and the flu (59). 
Supplemental oxygen is recommended in those with mildly low oxygen levels (a partial 
pressure of oxygen of less than 50–55 mmHg or oxygen saturations of less than 88%), as it 
may improve shortness of breath (6). Lung transplantation is an option for some patients 
while for others, lung volume reduction surgery to remove small part of damaged lung tissue 
is a beneficial treatment (60). Patients with emphysema caused by an alpha-1 antitrypsin 
(AAT) deficiency may be given infusions of AAT to help slow the progression of lung damage 
(61).  
 
As a future therapeutic approach, the WNT/β-catenin activation is shown to be promising. 
Lithium chloride-mediated WNT/β-catenin activation attenuated experimental emphysema in 
mice by decreasing airspace enlargement, improving lung function, reducing collagen 
content and elevating expression of alveolar epithelial cell markers (62). 
 
1.2.5 Pathogenesis of emphysema 
Understanding the pathogenesis of emphysema is quite complex and remains relatively 
poorly understood. Nevertheless, it is known that there are several key mechanisms have 
been implicated in the development of emphysema. One of them is the  imbalance between 
protease and antiprotease activity in the lung and considered as  the major mechanism 
causing emphysema. Increased alveolar cell death leading to failure in alveolar wall 
maintenance is also responsible for emphysema development. Besides, chronic 
inflammation, oxidative stress and accelerated senescence  also contribute to increased 
alveolar destruction as well as impaired lung maintenance and repair (Figure 2) (63). 
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Figure 2. Pathogenesis of emphysema development. The pathophysiology of emphysema  include cigarette smoke, air 
pollution or genetic deficiency of AAT derived oxidative stress, sustained inflammation, protease-anti-protease imbalance, 
enhanced apoptosis and premature senescence resulting in lung alveolar architecture destruction. Adapted from reference 
(64). 
  
1.2.5.1 Proteases/anti-proteases imbalance 
Proteases are enzymes responsible for breakdown of connective tissue parenchyma in lung 
and anti-proteases are to inactivate the function of proteases by covalently binding to them. 
An imbalance between proteases is a widely accepted mechanism behind the development 
of emphysema (65, 66). The concept of proteases/anti-proteases imbalance originates back 
in 1960s when subjects deficient in alpha1-antitrypsin (AAT), a major circulating inhibitor of 
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neutrophil elastase, were shown to be predisposed to an early onset of severe emphysema 
(67). A study on Pallid mice which are naturally deficient in AAT revealed that they suffered 
from an early development of emphysema compared to wild type mice with normal level of 
AAT (68, 69). Indeed, the imbalance may occur either by an unregulated excessive release 
of proteases or by a deficiency, reduced synthesis or increased breakdown of anti-proteases. 
The excessive proteolytic load is contributed by infiltrating phagocytic leukocytes, namely 
neutrophils and macrophages. These cells secrete a wide range of proteases, including 
serine proteases (neutrophil elastase, proteinase 3, cathepsin G), cysteine proteases 
(Cathepsins B, H, L, K and S) and a different types of matrix metalloproteases (MMPs) into 
emphysematous lungs (70-72). Among these, neutrophil elastase is a highly potent 
elastolytic enzyme and its intra-tracheal injection in experimental animals is capable of 
inducing emphysema (73). Another study demonstrated that mice lacking neutrophil elastase 
were 59% protected against emphysema (74). Secretory leukocyte protease inhibitor (SLPI) 
and elafin secreted by goblet cells, serus cells, Clara cells and alveolar type II (ATII) cells are 
both potent anti-proteases that can reversibly inhibit neutrophil elastase and in addition, SLPI 
can inhibit cathepsin G, trypsin, chymotrypsin and chymase while elafin inhibits proteinase-3 
(72). 
 
MMPs are released by inflammatory cells as well as lung structural cells. MMPs belong to a 
large family of zinc-dependent proteases that are able to degrade all components of the 
extracellular matrix (ECM). According to substrate specificity, MMP-1, MMP-8 and MMP-13 
are collagenolytic, MMP-2 and MMP-9 are gelatinolytic, MMP-3, MMP-10 and MMP-11 are 
stromelysins, while MMP-7 and MMP-12 are elastinolytic (75). The concentration and activity 
of MMP-1, MMP-2, MMP-8, MMP-9 and MMP-12 are found upregulated in sputum of COPD 
patients (76-81). The MMPs are inhibited by the tissue inhibitors of metalloproteinases 
(TIMP). Interestingly, MMP-12 is able to inactivate AAT while neutrophil elastase destroys 
TIMP-1, thus potentiating the action of each protease (74). Interestingly, MMP-12 is able to 
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inactivate AAT and thus keep neutrophil elastase active and the neutrophil elastase in turn 
destroys TIMP-1 to further potentiate the action of each protease (74). TIMP-1 is released at 
a significantly low level from alveolar macrophages of COPD patients compared to healthy 
smokers and non-smokers (82). The protective effect of TIMPs is further demonstrated by 
TIMP-3 knockout mice showing progressive airspace enlargement and collagen degradation 
(83). 
 
1.2.5.2 Apoptosis/proliferation imbalance 
There is increasing evidence suggesting that a disturbance of the balance between 
apoptosis and proliferation in lung tissue contributes to emphysema development. Imai and 
colleagues reported increased apoptosis of alveolar epithelial cells, endothelial cells and 
mesenchymal cells in emphysematous lung tissue associated with an increase in the 
activated subunits of caspase-3 and pro-apoptotic proteins Bax and Bad compared to control 
subjects. Interestingly, several studies also reported an increased cell proliferation was found 
in patients with emphysema (84, 85). Aoshiba and colleagues reported that intra-tracheal 
administration of active caspase-3 is capable of inducing epithelial apoptosis and results in 
emphysematous changes in mice (86).  
 
Apoptosis is found to be associated with decreased expression of vascular endothelial 
growth factor (VEGF), a protein required for cell maintenance (87). VEGF and VEGFR2 level 
were decreased in emphysema patients compared to healthy controls (88). Animal models 
demonstrate inactivation of VEGF leads to the early development of emphysema (89). A 
similar outcome was observed in another study where mice over-expressing placental growth 
factor (PIGF) showed to develop VEGF deficiency that led to alveolar apoptosis and 
emphysema (90). Apoptosis can be mediated by elastolytic activity in lung epithelial cells 
observed in a mouse model of emphysema. Mice double knockout for IL-1β and TNF 
receptors gene were treated with elastase showed less severe form of emphysema as well 
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as fewer apoptotic alveolar cells suggesting that elastase may contribute in alveolar 
apoptosis through IL-1β and TNF-dependent mechanism (91). A direct proteolysis of death-
inducing signals can also promote apoptosis. It has been shown that Fas ligand produced by 
epithelial cells can be shed and activated by proteolytic activity of MMP-7 and thereby 
mediates apoptosis (92). In addition to these mechanisms, an increased number of CD8+T 
lymphocytes in the lungs of COPD patients is reported to induce alveolar epithelial cell 
apoptosis through the release of perforins, granzyme-B and TNF-α (93, 94). 
 
1.2.5.3 Oxidative stress  
The lung is constantly exposed to either endogenous oxidants produced by metabolic 
reactions or exogenous air pollutants and cigarette smoke and thus could be highly 
susceptible to reactive oxygen species (ROS) mediated injury. Cigarette smoke is a complex 
mixture of >4,700 chemical compounds and each puff is considered to contain approximately 
1014 oxidative free radicals (95, 96). Among them superoxide radical (O2
•−) and nitric oxide 
(NO) are quite short-lived while tar-semiquinone persist in the lung for longer time periods 
(95) and react with oxygen to produce superoxide anion (O2-), the hydroxyl radical, and 
hydrogen peroxide that are abundantly found in smoker's lung (97). Endogenously, activated 
macrophages and neutrophils and also epithelial cells are known to release high levels of 
ROS via NADPH oxidase (98). Oxidative stress is able to activate transcription factors such 
as NF-kB and transcription factor activator protein-1 (AP-1) leading to increased release of 
inflammatory mediators including cytokines such as IL-8, TNF-α and nitric oxide (NO) (99).  
 
Endogenous oxidative stress contributing in emphysema has been demonstrated in several 
animal models. Most of these studies have investigated genes that are related to the cellular 
antioxidant response, such as Nrf2, thioredoxin 1 and SOD3 (extracellular superoxide 
dismutase or ECSOD). Nrf2 (NF-E2-related factor 2), is a basic leucine zipper type 
transcription factors that has been shown to bind to the antioxidant response element (ARE) 
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(100). Nrf2-knockout mice treated with elastase showed markedly exacerbated emphysema 
compared to wild-type mice. The emphysema severity correlated with the higher recruitment 
lung inflammatory cells in the initial stage of elastase treatment. The highly inducible 
expression of anti-oxidant and anti-protease genes observed in wild type alveolar 
macrophages was significantly attenuated in the lungs of Nrf2-KO mice (101). Thioredoxin-1 
(TRX) is a small protein with anti-oxidative effect shown to ameliorate lung inflammation and 
emphysema in mice model (102). A study on Superoxide dismutase (SOD3)--null mice 
exposed to cigarette smoke exposure or treated with elastase demonstrated airspace 
enlargement as well as impaired lung function and exercise capacity which were improved in 
mice overexpressing SOD3 or mice treated with pharmacological SOD analog. The 
improvement resulted from binding the analog with oxidative fragmentation of ECM such as 
heparin sulfate and elastin and thus attenuating their induction on inflammatory response 
(103). Lately, a study on mouse model of emphysema demonstrated that mice deficient in 
inducible nitric oxide synthase (iNOS) were protected against emphysema. Furthermore, 
treatment of wild-type mice with an iNOS inhibitor prevented as well as reversed already 
established emphysema demonstrating the pathophysiological role of oxidative stress in 
emphysema COPD (104).  
 
1.2.5.4 Inflammation 
It is widely accepted that inflammation is central to the development of COPD. Lung epithelial 
cells and inflammatory cells such as neutrophils, macrophages, CD8+T lymphocytes and 
dendritic cells release potent inflammatory mediators and proteinases which play a role in the 
progressive lung destruction in emphysema.  
 
The airway epithelium acts as a barrier between external environment and host. It is crucial 
for the maintenance of lung homeostasis by mucus production, ciliary movement, secretion 
of anti-microbial agents and immune response to noxious stimuli. Cigarette smoke exposure 
25 
 
triggers epithelial cells to release inflammatory mediators and proteases, such as CXCL8, 
TNF-α, TGF-β and IL-1β which in turn initiates and maintains chronic inflammation and 
airway remodeling (105-107). Cigarette smoke can also induce inflammatory responses in 
alveolar epithelial cells (108). Among inflammatory cells, macrophages are the key players in 
the inflammatory process in COPD. In smokers as well as in COPD patients, there is 
evidence demonstrating elevated levels of macrophages in airways, lung parenchyma, 
sputum and bronchoalveolar lavage (BAL) fluid. Cigarette smoke activates macrophages to 
induce the release of inflammatory mediators and matrix metalloproteinases (MMPs) which 
contribute to sustained inflammation and alveolar wall destruction (65, 109-111). Besides 
macrophages, numerous evidence have confirmed neutrophil as another a crucial 
inflammatory cell in COPD pathogenesis. Substantial numbers of activated neutrophils are 
quantified in sputum and BAL fluid of COPD patients (112-114). Neutrophils secrete a wide 
range of inflammatory mediators including neutrophil elastases, proteinase-3, cathepsin G as 
well as matrix metalloproteinase (MMP)-8 and MMP-9 contributing to alveolar destruction 
(115). In addition, in COPD patients, the airways harbor elevated numbers of lymphocytes, 
particularly the CD8+ T-cells (116). In animal models, exposure to cigarette smoke induced a 
surge in the number of dendritic cells (117). In accordance with this evidence, abundant 
dendritic cells are also observed in the airways and alveolar walls of smokers indicating the 
contribution of these cells in emphysema progression (118, 119). 
 
1.2.5.5 Cellular senescence  
Senescence is described as a permanent cell cycle arrest induced by cellular stress 
(premature senescence) or by exhaustion of cell's replicative capacity (120). Most recently, 
accelerated senescence or cellular aging has emerged as a strong hypothesis of COPD and 
it is now considered to be a disease of premature lung aging (121, 122).  As alveolar cell loss 
and reduced alveolar surface area contribute to lung structure destruction that is 
characteristics of emphysema, senescence could play a role in pathogenic alteration that 
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takes place during emphysema development and progression. In emphysematous lung, the 
repeated cell cycles of alveolar cell to compensate cells lost by apoptosis may shorten 
telomere length leading to replicative senescence (85, 123). However, the cigarette smoke 
exposure along with other stress factors associated with emphysema might also induce 
premature alveolar senescence without telomere shortening (124). Lately, a broad range of 
investigations has accumulated valid evidence on senescence being involved in COPD 
development (125). Telomere length in alveolar type II cells and endothelial cells in situ has 
been found to be significantly reduced in emphysema patients compared to control subjects 
(126).   
 
There have been experimental demonstrations that indeed various senescence markers are 
expressed in emphysematous lungs of COPD patients (121, 127). Senescence-associated β-
galactosidase, a common marker of cellular senescence, is regularly expressed in senescent 
cells (128). An increased expression of senescence-associated β-galactosidase was 
observed when lung fibroblasts of emphysema patients were cultured in vitro and compared 
to healthy smokers (124, 129). Exposing human lung epithelial cells to cigarette smoke 
extract also induced an enhanced expression of β-galactosidase and senescence-associated 
changes in cell morphology such as an increase in cell size and lysosomal mass, 
accumulation of lipofuscin, overexpression of p21 and irreversible growth arrest (127). The 
cyclin dependent kinase (CDK) inhibitors (p16, p21 etc.) regulating cell cycle progress are 
widely used markers for cellular senescence and reported to involved in emphysema. 
Genetic inactivation of p16 in BubR1 progeroid mice demonstrated delayed aging by 
preventing the formation of p16-positive senescent cells proving its role in senescence 
induction (130). A study done by Tsuji et al., demonstrated that lung tissue obtained from 
emphysema patients having significantly greater percentages of p16 and p21 positive 
alveolar type II cells and endothelial than non-smokers. A tumor suppressor and transcription 
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factor p53 regulates p21 and thus also plays a major role in the induction of cellular 
senescence in fibroblasts from COPD patients (131).  
 
In addition to cigarette smoke, aging is reported to be another major risk factor for COPD 
patients (132). Both aging and cigarette smoke induce p16 expression in lung tissue suggest 
the possibility that cellular senescence plays a crucial role in both the smoke-related as well 
as and the age-related pathogenic mechanisms of COPD (125, 133). Besides, telomere 
length in both of these cell types were greatly reduced compared to healthy controls. In 
addition, p16 expression level was inversely correlated with PCNA, a proliferation marker 
expression level. Most importantly, there was a strong correlation between cellular 
senescence and airflow limitation measured as FEV1% values (126). γH2AX is a marker for 
DNA double strand breakage and recent study reported the presence of significantly high 
number of γH2AX foci in the alveolar type I and II cells and endothelial cells of the lungs of 
COPD patients compared to healthy smokers or control subjects. The foci were associated 
with cellular senescence, apoptosis and pro-inflammatory changes (134).  
 
Sirtuin1 or SIRT1 is an anti-aging and anti-inflammatory protein, is a metabolic NAD(+)-
dependent protein/histone deacetylase that regulates pro-inflammatory mediators by 
deacetylating histone and non-histone proteins (135). Peripheral lungs of smokers and 
patients with COPD showed decreased levels of nuclear SIRT1, as compared with 
nonsmokers. In vitro study on macrophages treated with cigarette smoke extract showed 
decreased levels of SIRT1 which was associated with an increased acetylation of RelA/p65 
NF-κB (136). It has been demonstrated SIRT1 protecting against emphysema by FOXO3-
regulated reduction of premature senescence (137). Treatment of endothelial cells from 
COPD patients with a SIRT1 activator (resvaratrol) is shown to rescue H2O2-induced 
senescent phenotype back to normal state (138).  
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1.2.6 Animal Models of Emphysema  
1.2.6.1 Elastase-induced emphysema model 
The application of elastases such as porcine pancreatic elastase (PPE) is a well-established 
animal model as it induces irreversible progressive changes in lung structure and function 
that are typical characteristics of emphysema (139, 140). The first reproducible animal model 
of emphysema was established by Gross et al in 1965 by intratracheally delivering plant 
proteinase papain in rats (141). Subsequent studies further confirmed that that only enzymes 
with the capacity to solubilize the ECM protein elastin can produce both morphological and 
histological changes that are comparable to pan-acinar emphysema observed in human 
subjects (25). More recent studies have been applying either porcine pancreatic elastase 
(PPE) or human neutrophil elastase (HNE) as an emphysema model in animals. Crude 
extract of human neutrophils and later purified HNE capable of inducing emphysematous 
changes and these studies led to the proteinase/anti-proteinase hypothesis that emphysema 
develops as a result of an influx of inflammatory cells into lungs triggering release of 
excessive proteases that ultimately destroys the lung alveolar architecture (142). Consistent 
quality human neutrophil elastase is commercially available yet relatively expensive whereas 
PPE offers the advantages of being cost-effective and easy to obtain. PPE application 
produces consistent and significant airspace enlargement accompanied with inflammatory 
cells accumulation within the lungs of rodents, guinea pigs, dogs and primates (25, 143). 
PPE is a 25.9 kDa globular protein consists of a single polypeptide chain of 240 amino acids 
cross-linked by four disulfides bridges. Unlike other elastases that hydrolyze a wide range of 
protein substrates, PPE specifically breaks down elastin (144). Despite its known half-life of a 
few hours and a turn-over rate of 99% in four days (145, 146) PPE triggers a continuous 
airspace enlargement and lung function decline even after stimulus cessation (139, 140) 
which mimics the irreversible structural changes occurring in the lungs of COPD patients 
even after smoking cessation (147). Most recently, a study monitored and described a PPE-
induced emphysema progression in animal model for 12 weeks monitored by morphometry 
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and micro-computed X-ray tomography (148). However, a shortcoming of elastase model is 
that cannot be used to study all aspects of COPD as it reflects only one main symptom, e.g. 
pulmonary emphysema. This model lacks significant inflammatory components, resulting in 
the lack of chronically persisting inflammatory cells (chronic bronchitis) and absence of small 
airway remodeling. Nevertheless, as an emphysema model the elastase model remains a 
useful tool with great advantages: a) it is relatively simple to perform, b) highly reproducible, 
c) models could be established by a single treatment with an inexpensive reagent in a short 
period, d) requires less time and less labor as compared to the usual 6-month long cigarette 
smoke exposure and e) most importantly, emphysema progression could be reliably monitor 
by lung function tests (149). Despite the pros and cons, elastase-induced emphysema is one 
of the most common means of establishing emphysematous phenotypes in animal models  
to better understand the pathomechanism of the disease.  
 
1.2.6.2 Cigarette smoke-induced emphysema model 
Given its involvement as the major risk factor of COPD, cigarette smoke (CS)-induced 
emphysema model would be an important tool as well as an attractive approach to 
 investigate the disease. Unlike elastase model, the CS-induced emphysema is accompanied 
by a significant amount of inflammation. The first cigarette can trigger neutrophil recruitment  
which is followed by an influx of macrophages. The early neutrophil influx is associated with 
enhanced degradation of  collagen and elastin fibers (150). A shortcoming of the model is 
that the severity varies from species to species. CS exposure causes highly prominent 
emphysema in guinea pigs whereas it induces minimal disease development in rats or 
causes nonspecific particle overload effectif smoked too heavily (151, 152). The effectivity of 
CS model is also limited by genetic factors influencing susceptibility. Among commonly used 
mouse stains in laboratories, the AKR/J strain shows significant emphysema whereas A/J, 
SJL, and C57BL6/J strains show mild and NZWLac/J stain is resistant to CS induction (153). 
Besides, the brand and number of cigarettes, exposure time, sex and age of the animals 
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exposed are also important factors modulating lung's response to CS-induced emphysema 
development. In addition, there are marked differences between main-stream smoke (the 
smoke that emerges from the mouth-end of the cigarette while smoking) and side-stream 
smoke (the smoke that emerges from the lit-end of the cigarette between puffs) which also 
contributes in varying emphysema severity in animal models (154). A major disadvantage of 
CS model is that it takes considerably more time to induce significant pathological changes in 
the lung (starting from 4 months of exposure) (155). Furthermore, CS exposure of animals 
for up to 6 months only produces a mild disease, probably equivalent to human Global 
Initiative on Chronic Obstructive Lung Disease (GOLD) stage 1 or 2 (6).  
 
1.3 Post-translational modification of arginine 
Post-translational modifications (PTM) refer to the proteolytic cleavage or the addition of a 
modifying group to one or more amino acids of a protein by covalent bonding. PTMs, such as 
phosphorylation, ubiquitination, acetylation, SUMOylation and methylation can regulate 
activity, localization, turn-over and interaction of a protein with other proteins and thus play a 
pivotal role in functional changes of histone and non-histones proteins (156).  
 
Arginine residues within histones and non-histone proteins are subject to various PTM and 
have been linked to a variety of important cellular processes like transcriptional regulation, 
translation, and DNA repair (157). Therefore, here, we focus on post-translational 
modifications on arginines. Arginine is classified as a semi-essential or conditionally essential 
amino acid in mammals (158). It is a positively charged amino acid which is involved in 
formation of hydrogen bond and interaction with protein or nucleic acids. Arginine PTM was 
first described with the identification of citrullination or deimination in protein that removes an 
imine group from arginine side chain and converts arginine into neutral, hydrophilic citrulline 
(159, 160). Till to date, arginine is known to be modified by four types of enzymatic PTMs: 
methylation, citrullination, phosphorylation, and ADP-ribosylation and two types of non-
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enzymatic PTMs such as carbonylation, advanced glycation end-products (161). Of all these 
modifications of arginine, the methylation has been the most extensively characterized due to 
its biological role. 
 
1.3.1 Protein Arginine Methylation 
About 0.5% of arginine moieties are methylated in mammals (162). Regulation of arginine 
methylation is associated with crucial cellular processes including transcriptional regulation, 
translation, and DNA repair (157). The existence of methyl group on arginine in proteins first 
came into notice back in 1967 (163). Methylation of an arginine moiety results in the addition 
of one or two methyl groups to its guanidino nitrogen atoms (164). In contrast to citrullination, 
methylation does not neutralize the positive charge in arginine, but increases the 
hydrophobicity of proteins (165). In mammals, three kinds of methylated arginine have been 
discoverd so far. These are: ω-NG-monomethylarginine (MMA), ω-NG,NG-asymmetric 
dimethylarginine (ADMA) and ω-NG,N′G-symmetric dimethylarginine (SDMA) (164). Among 
them, ADMA is the most commonly occurring derivative (162).  All three derivatives can be 
found on distinct protein species in the cytoplasm, nucleus, and organelles of mammalian 
cells (157). One common feature of the majority of methylated arginine residues is that they 
are often flanked by one or more glycine residues (164).  
 
1.3.2 Characteristics and classification of protein arginine methyltransferases (PRMTs)  
Although protein arginine methylation was reported 40 years ago (163), the first gene coding 
for the arginine methyltransferase enzyme was identified only a decade ago (166, 167). 
PRMT-encoding genes have been identified from the sequenced genomes of yeasts, worm, 
fly, plants, and mammals (157). Currently, 11 PRMT members, differing in sequences and 
substrate specificities is known to exist and already has been characterized (168). All PRMTs 
contain a conserved core region that includes a methyltransferase (MTase) domain, a β-
barrel and a dimerization arm (169).  
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Figure 3: Classification of PRMTs. Types I, II and III PRMTs catalyze the formation of monomethylarginine (MMA) on one 
of the terminal guanidino nitrogen atoms. Type I enzymes catalyze the subsequent formation of asymmetric dimethylarginine 
(ADMA) whereas type II enzymes generates symmetric dimethylarginine (SDMA). Type III PRMTs catalyze monomethylation 
only. Type IV enzyme only described in yeast catalyzes monomethylation of the internal guanidino nitrogen. Adapted from 
reference (170). 
 
PRMTs are AdoMet-dependent methyltransferases as they catalyze transfer of specific 
methyl group from the ubiquitous cofactor S-adenosyl-L-methionine (AdoMet) to arginine 
residues of biologically important target proteins in the cell (171). Initially, PRMTs were 
reported to methylate histone proteins but more recently, PRMT-mediated methylation of 
non-histone proteins has been under detail investigation. The non-histone proteins 
methylated by PRMTs are either RNA binding proteins or those that are involved in 
transcription (164, 172, 173). Usually, proteins that harbor glycine- and arginine-rich patches 
(GAR motifs) are often substrates for PRMTs (174). Another prominent methylation site for 
33 
 
PRMTs is motifs consists of motifs are proline-, glycine-, methionine-, arginine-rich patches 
(PGM motifs) (175) that are found in a number of splicing factors (176).  
 
According to the methylarginines derivatives they catalyze, PRMTs can be classified into four 
types (Figure 3 and 4) (177). All members of PRMT family catalyze the formation of ω-NG-
monomethyl arginine (MMA). In addition, type I PRMTs catalyze the formation of asymmetric 
ω-NG, NG-dimethylarginine (ADMA) and this class includes PRMT1, PRMT2, PRMT3, 
PRMT4/coactivator-associated arginine methyltransferase 1 (CARM1), PRMT6, PRMT8 and 
RMT1 (170). Type II PRMTs including PRMT5, PRMT7, FBXO11 and Hsl7 catalyze the 
formation of symmetric ω-NG, N′G-dimethylarginine (SDMA) (178). However, it is not well 
characterized whether PRMT7, FBXO11, and Hsl7 are type II PRMT or a type III PRMT 
which is only able to form MMA monomethylate arginines (170, 179). Type III PRMTs family 
consists of T. brucie homolog of human PRMT7, TbPRMT7 (180). Type IV enzymes catalyze 
the formation of monomethylation of the internal guanidino nitrogen of  arginine (δ-NG-
monomethyl arginine) and so far RMT2 from S.cerevisiae and C.albicans have been 
demonstrated to harbor this activity (181, 182). 
 
1.3.3 PRMT family members 
PRMT1: It was first identified as a single gene product by sequence similarity to the yeast 
arginine methyltransferase Hmt1/Rmt1 and it is reported to be the predominant mammalian 
type I PRMT as it performs over 80% of PRMT activity in cell (183). It was the first human 
PRMT isolated and well characterized. In human, there exist 3 major transcript variants of 
PRMT1 (183). The common substrates of PRMT1 are a number of hnRNP molecules and 
methylation modulates the shuttling of these proteins between the cytoplasm and the nucleus 
(184). PRMT1 also methylates histone H4 at arginine 3 that functions as a transcriptional 
activation marks (185). Gene ablation experiments in mice showing that the PRMT1 null 
embryos die at embryonic day 6.5 proved PRMT1 to be essential for survival (186).  
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PRMT2:  It is a unique member of PRMT family. It harbors an SH3 domain at its N-terminus 
(187). Human PRMT2 is reported to methylate histone H4 (188) as well as hnRNP E1B-AP5 
(189). It also plays a role of a coactivator for androgen and estrogen receptors (190, 191). 
Unlike PRMT1, the PRMT2-null mice are viable and physiologically normal (192). Increased 
expression of PRMT2 in alveolar type II cells is observed in choric hypoxia, a potent stimulus 
for COPD (193). 
 
PRMT3: It was discovered by its association with PRMT1 (187, 194). PRMT3 is a ribosomal 
protein methyltransferase that regulates the cellular levels of ribosomal subunits (195). A 
distinct feature of this PRMT family member is that it contains a zinc-finger domain at its N-
terminus and this domain functions as its substrate-recognition module (194). By methylating 
its zinc-finger-dependent ribosomal protein subunit S2 (rpS2), PRMT3 inhibits its 
ubiquitination (196, 197). PRMT3 null mouse embryos are small in size, but the mice survive 
after birth and grow to a regular healthy size in adulthood. The ribosome protein rpS2 is 
hypo-methylated in the absence of PRMT3, which demonstrates that it is an in vivo PRMT3 
substrate (198). 
 
PRMT4: It binds the steroid receptor coactivators (SRC1-3) and has clear transcriptional 
coactivator activity itself, thus its name-the coactivator associated arginine methyltransferase 
1 or CARM1 (199). It was the fourth arginine methyltransferase described. It is also referred 
to as PRMT4. As PRMT4/CARM1 is the main focus of this dissertation, it is discussed in 
detail in the following section (1.3.4). 
 
PRMT5: This member was identified as a Janus kinase 2 binding protein in a yeast two 
hybrid screening and hence was called JBP1 (200). It is shown to methylate myelin basic 
protein, fibrillarin and histones H2A, H3 and H4 (201, 202). PRMT5-mediated methylation of 
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sphingomyelin (Sm) and survival of motor neuron (SMN) contributes in spliceosome 
assembly (203). PRMT5 is also important for facilitating ATP-dependent chromatin 
remodeling (204).  
 
PRMT6: It is a 41.9 kDa Type I methyltransferase with auto-methylation activity (205). Its 
substrates include nuclear scaffold protein HMGA1a, DNA polymerase β, the HIV Tat and 
histone H3 (206-209).  
 
PRMT7: A characteristic of PRMT7 is that it contains two functional AdoMet-binding motifs. 
Another marked feature is that it mainly catalyzes the formation of MMA but not DMA and 
thus labeled as a type III enzyme (210). Knockdown of PRMT7 shows upregulation of gene 
expression regulating DNA repair (211).  
 
PRMT8: It was originally identified through its high degree of sequence similarity (over 80%) 
to PRMT1. The unique feature of PRMT8 is that it has a unique N-terminus harboring a 
myristoylation motif which facilitates its association with the plasma membrane (212). It is 
known to poses auto-methylation activity at R58 and R73 in the N-terminal region (213).  
 
PRMT9: The protein encoded by the gene 4q31 is identified as human PRMT9 (214). With 
845 amino acids, it is the largest member in the PRMT family. It also harbors two 
tetratricopeptide repeats (TPR) motifs contributing in protein-protein interactions (172). 
PRMT10 and PRMT11 are not fully characterized. 
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Figure 4: Structural characteristics of PRMT family members. All PRMTs contain at least one methyltransferase (MTase) 
domain. Additional domains are: Znf (zinc finger), Myr (myristoylation), F-box, TRP (tetratricopeptide) and NosD (nitrous 
oxidase accessory protein). In addition, PRMT4 has a unique C-terminal region, PRMT7 or PRMT10 has two catalytic 
domains. Adapted from reference (168). 
 
1.3.4 Coactivator-Associated Arginine Methyltransferase 1, CARM1 
PRMT4 or CARM1 was identified in the yeast two-hybrid screening assay in 1999. It was 
found to be associated with a, p160 steroid receptor coactivator, GRIP1 (199). As it binds the 
steroid receptor coactivators and poses a transcriptional coactivator activity, thus it was 
named as the coactivator-associated arginine methyltransferase 1 (CARM1).  
 
1.3.4.1 Structure of CARM1 
CARM1 harbors 608 amino acids in mouse as well as in human. The CARM1 crystal 
structure was solved by two groups, providing insight into its mechanism of action (215, 216). 
Structurally, CARM1 can be divided into three domains. It contains a methyltransferase 
catalytic core flanked by characteristics pre (N terminal) and post (C terminal)-core segment 
(215). The catalytic core of other PRMTs such as PRMT1 or PRMT3 shares 49% sequence 
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similarities whereas, CARM1 shares only 34% sequence similarity (216). The core is folded 
into two domains that are connected by a conserved cis-proline residue.  
 
Figure 5: Structural organization of CARM1. The monomer consists of the N-domain (blue), C-domain (red), dimerisation 
arm (yellow) and C-extension (green). Adapted from reference (216). 
 
The first domain at the N-terminal end contains a typical Rossmann Fold (RF) and two 
terminal Helices αX and αY was also found in the structure of PRMT3 (215, 217). The RF 
topology contains the S-Adenosyl methionine (SAM or AdoMet) consensus fold which is 
conserved in all AdoMet-dependent methyltransferase enzymes (218). The second domain 
consists of a β-barrel to which an arm harboring a four-helix segment is attached. This arm 
contributes in the dimerization process of CARM1 as well as other PRMTs (215). Crystal 
structure of core region reveals the existence of a co-factor-dependent formation of a 
substrate-binding groove acting as an access channel for arginine to the active site. This 
groove is supported by the initial 8 residues from the post-core segment called C-extension 
that is uniquely present only in CARM1 but not in other PRMTs. Deletion of C-extension 
nullify the methyltransferase activity of CARM1 to Arg17 of histone H3, proving the 
contribution of this segment to the enzymatic activity of the core domain (216). The N-
terminal segment varies in size and poses a Pleckstrin homology (PH) domain (215) (Figure 
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5, blue region). PH domain is a protein domain of approximately 120 amino acids that occurs 
in a wide range of proteins involved in intracellular signaling (219). The PH domain in 
CARM1 can assume different position and acts as a wobbly domain (220). It is connected to 
the catalytic core by a linker although both domains can behave independently. However, 
during co-activation of gene expression, they cooperate upon binding to other proteins (215).  
 
1.3.5 Molecular function of CARM1 
1.3.5.1 Methyltransferase activity 
Enzymatic activity is critical for CARM1 to perform it biological roles. In a recent study on 
mouse model an enzyme-dead version of CARM1 knock-in embryo and mouse embryonic 
fibroblasts (MEF) cells were generated to produce enzymatically inactive CARM1. Lack of 
methyltransferase activity demonstrated embryo lethality, aberrant adipocyte differentiation, 
impaired T cell development and diminished transcriptional coactivator activity proving that 
enzymatic activity of CARM1 is essential for all of its cellular functions in vivo (221).  
 
1.3.5.2 Transcriptional coactivator 
CARM1 is considered as a coactivator for many transcriptional factors. For example, it 
cooperates with PRMT1 and p300/CBP in ER-dependent transcriptional activation but 
CARM1 depends on another transcription factor, p160 for its coactivator function, showing 
that CARM1 is a secondary coactivator rather than acting as the primary transcriptional 
activator (222, 223). Although CARM1 was initially identified as estrogen and androgen 
receptor coactivator, it is now emerging as coactivator of large number of transcription 
factors and thus acts as a molecular switch to control their expression. This includes, p53, 
p21, p16, SIRT1, NF-kB, LEF1/TCF4, E2Fs, cyclin E1, PPARγ, RUNX1, Wnt signaling 
molecule β-catenin and so on  (222-228). This suggests CARM1 plays a role in cell 
proliferation and cell survival. As a coactivator for PPARγ, CARM1 promotes preadipocytes 
to differentiate towards adipocytes (226). The recruitment of CARM1 to NF-κB target 
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promoter positively regulates NF-κB mediated expression of pro-inflammatory genes such as 
G-CSF, MIP-2, MCP-1, ICAM1 and IP-10 (229).  
 
1.3.6 Substrates of CARM1  
Proteins that harbor a glycine and arginine rich motif (GAR motif) are usually the ideal 
substrate for PRMTs (174). In contrast, CARM1 is shown to be unique in substrate specificity 
as it does not methylate GAR motif. Actually, there is no particular motif that is recognized by 
CARM1. This lack of motif specificity makes it difficult to find potential substrate for CARM1 
using in silico tools that search primary protein sequences. Despite this limitation, CARM1 
has been demonstrated to methylate a wide range of proteins crucial for gene expression. 
The substrates of CARM1 can be classified into two broad classes: chromatin remodeling 
proteins and RNA binding protein and splicing factors. 
 
1.3.6.1 Chromatin remodeling proteins    
The first CARM1 substrate identified was histone H3 (199). It is a major in vivo substrate for 
CARM1. CARM1 catalyzes mono- and asymmetrical dimethylation on R2, R17 and R26 sites 
in histone H3 which correlates with activation of estrogen-receptor-target gene, pS2 (230). 
Arginine methylation is reported to take place prior acetylation of H3 by CREB-binding 
protein (CBP). H3 K18 and K23 acetylation promotes efficient methylation at R17 of H3 and 
correlates to gene activation (231). Non-histone proteins methylated by CARM1 include 
CBP/p300, SRC3 and RNA polymerase II (232-235). 
 
1.3.6.2 RNA binding protein and splicing factors 
Additional CARM1 substrates have been identified by large-scale enzyme reactions on 
protein arrays. These include the poly (A)-binding protein 1 (PABP1) and the T cell-specific 
factor TARPP. PABP1 is by far the most prevalent substrate identified for CARM1 (236). 
Candidate approaches also identified other RNA-binding proteins, HuR and HuD and 
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methylation affects their mRNA-stabilizing properties and the half-life of their target mRNAs 
(237). Splicing factors are another class of transcriptionally important substrates for CARM1. 
Splicing factors couple transcription with mRNA processing (238). CA150, a splicing factor is 
methylated by CARM1 and this post translational modification promotes an interaction of 
CA150 with the methylation mark recognizing Tudor domain of spinal muscular atrophy 
protein, SMN. The CARM1 dependent methylation of CA150 is suggested to induce exon-
skipping. In addition to CA150, other splicing factors methylates by CARM1 include SmB, 
U1-C and SAP49 (175). 
 
One established mechanism by which CARM1 regulates senescence is via methylation-
dependent modulation of its substrate, HuR. It is an RNA binding protein specifically 
methylated by CARM1 mainly at Arg217 of its hinge region (239). HuR methylation determines 
its binding and stabilization of its target gene transcripts (239, 240). 
 
CARM1-SIRT1 axis 
Along with decreasing CARM1, the senescent fibroblasts show a decrease in SIRT1 
expression (241). SIRT1 or Sirtuin 1 is a member of SIRT family and is an NAD+-dependent 
lysine deacetylase functioning in multiple cellular events but most importantly in control of 
lifespan and thus acting as an anti-senescence gene (242). It has been demonstrated that 
there is a reduction of SIRT1 expression in the lung of smoker and COPD patients (136). In 
an animal model of COPD, SIRT1 protects against emphysema by reduction of premature 
senescence (137). CARM1 indirectly regulates SIRT1 expression by methylating HuR and 
induce its association with SIRT1 mRNA; this association in turn enhances SIRT1 transcript 
stability by prolonging mRNA half-life (Figure 6) (240). 
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Figure 6 . Regulation of SIRT1 trancript stabilization by CARM1. CARM1 methylation of HuR increases HuR/SIRT1 
binding and subsequently stabilizing SIRT1 at mRNA level leading to maintaing a normal level of SIRT1 protein. The 
decrease in CARM1 is associated with a decrease in HuR methylation and, consequently, of HuR/SIRT1 binding, resulting in 
less SIRT1 mRNA and protein. Adapted and modified from reference (239). 
CARM1-p21/p16/p53 axis 
The common senescent phenotypes of cells are characterized by overexpression of CDK 
inhibitors such as p16 and p21 and checkpoint inhibitor p53 and Rb (243). In contrast to 
transcript stabilization, CARM1 can also destabilize transcripts for senescence marker 
genes. CARM1-dependent post-translational methylation of HuR enhances its binding with 
p16 or p21 mRNA and leading to transcript degradation to protects against senescence (224, 
239). CARM1-mediated methylation of HuD, another mRNA binding protein also shown to 
regulate the half-life of the p21 transcript (237).   
 
1.3.7 Regulation of CARM1  
Among all PRMTs, distinct aspects of CARM1 activity have been subjected to be regulated 
by several post-translational modifications such as phosphorylation and auto-methylation. 
 
1.3.7.1 Phosphorylation  
CARM1 is negatively regulated by phosphorylation of its serine residues. Three such sites 
have been reported to be phosphorylated on sites and two of them contribute in regulation of 
its enzymatic activity during mitosis (244, 245). Phosphorylation of serine 229 prevents 
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dimerization of CARM1 and thus abrogates methyltransferase activity of CARM1 (245). 
Phosphorylation on serine 217 blocks binding of S-Adenosylmethionine (SAM or AdoMet) to 
the catalytic domain and turns CARM1 into an inactive state. In addition, this modification is 
also involved in PRMT4/CARM1 trans-location from nucleus to cytoplasm in G2/M transition 
(244). Recently, a third phosphorylation occurring at serine 448 is identified to facilitate a 
direct interaction of CARM1 with estrogen receptor (ERα) and leads to ERα-mediated 
transcription (246).  
 
1.3.7.2 Auto-methylation 
Auto-methylation event was first observed in a CARM1 homologue (AgCARM1) in the 
mosquito model Anopheles gambiae, AgCARM1 is dimethylated at arginine 485 in vivo 
(247). In mouse, the auto-methylation site is at arginine 551 (in exon 15). Mutating this 
arginine into lysine does not interrupt methyltransferase activity. However, it impairs 
coactivator function of CARM1 and negatively regulates CARM1-mediated transcription and 
mRNA splicing (248). Further study on endogenous CARM1 isoforms reveals that alternative 
splicing serves as the determinant for CARM1 auto-methylation as this modification occurs 
only in full length CARM1 protein but not in exon 15 deleted isoform (249).  
 
1.3.8 Cellular function of CARM1 
1.3.8.1 Role in Proliferation and Differentiation 
Proliferation 
CARM1-mediated arginine methylation of transcription factor Sox9 prevents its interaction 
with β-catenin and thus regulating cyclin D1 expression to induce chondrocyte proliferation 
(250). CARM1 has also been implicated in unregulated cell proliferation. Dysregulated 
CARM1 is linked to estrogen-induced proliferation of breast cancer cells via playing 
coactivator role for E2F1 and cyclin E1 expression (251, 252). CARM1 mRNA was found 
overexpressed in tumors in grade 3 breast cancer patients (252). CARM1-PELP1 axis is also 
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implicated in breast cancer. PELP1, a proto-oncogene recognizes histone arginine 
methylation by CARM1 functionally interacts with CARM1 and modulates its coactivator 
functions. Inhibition of CARM1 expression or blocking its function reduces oncogenic function 
of PELP1 (253). Elevated CARM1 levels in breast cancer and in prostate cancer is 
associated with high-levels of an oncogenic coactivator AIB1 as its activity and stability is 
regulated by CARM1-dependent methylation (234, 252, 254-256). CARM1 is also shown to 
be overexpressed in human colon cancer cell line (257). In addition, microarray analysis of 
tissue from colorectal cancers patients confirmed CARM1 to be significantly elevated in the 
colorectal cancers (258). CARM1 promotes clonal survival and anchorage-independent cell 
growth via Wnt/β-catenin signaling. Its methyltransferase domain interacts with β-catenin 
which then recruits CARM1 to the promoter of Wnt target gene and co-activates transcription 
(257). More importantly, CARM1 along with PRMT1 are recently found particularly 
overexpressed in patients with Non-Small Cell Lung Carcinomas (NSCLC) and CARM1 
expression is linked to lung tumor differentiation but not to cell survival (259). All these 
evidence suggest that increased CARM1 expression leads to pathological changes 
contributing in tumorigenesis. On the contrary, loss of CARM1 leads to hyperproliferation of 
lung alveolar epithelial cell indicating importance of CARM1 for proper proliferation (251). An 
explanation of this opposite effect could be the difference in availability of CARM1 target 
proteins in alveolar versus tumor cells (260).   
 
Differentiation 
CARM1 is shown to be crucial for life as CARM1-null mice die from breathing failure 
immediately after birth. Further analysis revealed that the lung of CARM1 deficient mice 
showing defective maturation of alveolar epithelial type II (ATII) cells and impaired trans-
differentiation evident by an absence of alveolar epithelial type I (ATI) cells (232, 251). 
Furthermore, CARM1-null embryos shows lack o brown fat showing cells not expressing 
CARM1 lose the potential to differentiate into mature adipocytes (226). Besides, CARM1 is 
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also involved in differentiation of chondrocytes and myoctes for skeletal muscle development 
(204, 250). Loss of CARM1 leads to hypomethylation of cAMP-regulated phospho-protein in 
thymocytes resulting in defective T cell differentiation (261). Functional CARM1 is also 
reported to regulate proper fetal hematopoesis (262). The functional impact of the CARM1-
SIRT1 axis is implicated in human embryonic stem cell differentiation (240).  
 
1.3.8.2 Role in Senescence  
CARM1 shows significant reduction in explicatively senescent human diploid fibroblast cells 
(WI-38 fibroblasts) coupled with a marked downregulation of asymmetrically-methylated 
proteins. Beside replicative senescence, premature senescence induced by H2O2 also 
decreases CARM1 level (263). CARM1-meditated methylation of HuRis reported to 
supresses cellular senescence in fibroblasts to regulate the turnover of cyclin A, cyclin B1, c-
fos, SIRT1, and p16 mRNAs (224). Reduced level of CARM1 is also observed in testis, 
thymus and heart of 24-month-old rats compared to 6-month-old rats, suggesting CARM1 is 
regulated in age-dependent manner (264).  
 
1.3.9 Protein Arginine methylation in COPD 
Asymmetric dimethylariginine (ADMA), the catalyzed product of type I PRMTs ADMA has 
been abundantly detected in urine, plasma, cerebrospinal and most importantly in 
bronchoalveolar lavage (BAL) fluids (265-268). PRMTs regulate senescence in COPD 
through ADMA via direct effects on gene expression and protein function, as shown by  
methylated HuR-mediated stabilization of SIRT1 (137, 240). In addition, PRMTs can also 
regulate oxidative stress in COPD by regulating nitric oxide (NO) production. It is well known 
that NO plays critical role in endothelial dysfunction and oxidative stress in COPD (269) and 
ADMA is a potent inhibitor of nitric oxide synthase (NOS) isoforms (nNOS, iNOS, and eNOS) 
(270). Therefore, inhibition of NOS and subsequently altered NO generation is may be 
another way how PRMTs maintain lung homeostasis. However, the lung itself generates a 
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significant amount of ADMA which suggests that a dysregulated ADMA metabolism in the 
lung might trigger a chronic lung diseases including COPD (268).  
 
Furthermore, several studies have investigated the relationship between cigarette smoke and 
ADMA levels although they demonstrate conflicting results. Some studies reported 
decreased reduced ADMA levels reflecting a decline in PRMT activity in smokers compared 
with non-smokers while others showed increased ADMA levels in smokers (271, 272). In 
vitro studies using cigarette smoke extract (CSE)-treated cell also show contrasting data. For 
example, 10% CSE-treated human endothelial cells lead to decreased intracellular ADMA 
concentration (272) while others reported upregulation of ADMA levels under such conditions 
(273). Despite the contrasting results, it can be deduced that cigarette smoke is an important 
regulator of ADMA and PRMTs. However, more conclusive evidence is necessary to assess 
whether COPD has a valid association with dysregulated PRMT expression and activity. 
 
A recent analysis of methylarginine metabolism in the mouse lung, heart, liver, and kidney 
reveals the lung to be a major source of CARM1. The abundance of CARM1 expression in 
lung in comparison to other organs suggests its possible role in maintaining lung 
homeostasis (264, 274). Indeed, CARM1 knockdown resulted in the dysregulated 
proliferation and impaired trans-differentiation of alveolar epithelial cell (251). Thus, abundant 
pulmonary expression accompanied by its ability to control cell proliferation and 
differentiation makes CARM1 a potential target for further investigations on COPD 
development and progression.  
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1.4 Aim of the study  
Emphysema-the major component of COPD is characterized by alveolar damage leading to 
progressive decline in lung function. Currently, there is no specific treatment for emphysema. 
There is growing evidence that emphysema is promoted by an accelerated senescence of 
the lung cells. However, the key regulator of senescence which could be crucial in COPD 
pathogenesis have not yet been identified. We hypothesized that CARM1 deficiency is 
involved in emphysema development by modulating cellular senescence in the lung. For our 
study purpose, we used a porcine pancreatic elastase (PPE)-induced emphysema model in 
mouse. To test our hypothesis, we aimed: 
a) to assess the contribution of CARM1 expression in a progressive emphysema mouse 
model 
b) to compare the emphysema susceptibility between CARM1 haploinsufficient mice and 
wild type mice after elastase treatment  
c)  to evaluate the induction of cellular senescence by siRNA-mediated knockdown of 
CARM1 in ATII-like LA4 cells in vitro.  
Thus the overall working-hypothesis of this thesis was that CARM1 regulates the 
development and progression of emphysema. 
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2. MATERIALS AND METHODS 
2.1 MATERIALS 
2.2.1 Antibodies 
Table 2: 
Antibodies (Abs) Host Dilution Suppliers 
Anti-CARM1 polyclonal Rabbit IHC 1:150, 
WB 1:750 
Abcam, ab87910, Cambridge, UK 
Anti-Phospho-CARM1 
polyclonal 
Rabbit WB 1:500 Abnova, PAB25896,  Taipei, 
Taiwan. 
Anti-SIRT1 polyclonal 
 
Rabbit IHC 1:100 
WB 1:1000 
Millipore, 07131, Schwalbach, 
Germany 
Anti-p16  polyclonal 
 
Rabbit IHC 1:50 
WB 1:200 
Santa Cruz, sc-1207, Heidelberg, 
Germany 
Anti-p21  polyclonal Rabbit WB: 200 Santa Cruz, sc-397 Heidelberg, 
Germany 
Anti-SP-C  polyclonal Rabbit IF 1:100 
 
Millipore, 3786, Schwalbach, 
Germany 
Anti-SP-C  polyclonal Rabbit IHC: 1:50 Bioss, bs-2337R, Woburn, MA, 
USA 
Anti-β-galactosidase 
 
Rabbit IHC 1:50 Life Technologies, A-11132, 
Dermstadt, Germany 
Anti-T1α polyclonal    Mouse WB 1:4000  
 
R&D, AF3244, Minneapolis, 
Minnesota, USA 
Anti-β-actin monoclonal  
HRP conjugated 
Rabbit WB 1:50000  
 
Sigma-Aldrich, Taufkirchen, 
Germany  
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Anti-rabbit IgG Alexa Fluor 
488 conjugated secondary Ab 
Donkey IF 1:250  Invitrogen, Darmstadt, Germany 
Anti-rabbit IgG HRP 
conjugated  secondary Ab 
Goat WB 1:2500 Abcam, Heidelberg, Germany 
DAPI, 4',6-diamidino-2-
phenylindole 
Rabbit  IF 1:2000 Sigma-Aldrich, St.Louis, USA 
Anti-goat IgG Alexa Fluor 568 
secondary antibody 
Donkey IF 1:250  
 
Invitrogen, Darmstadt, Germany 
Anti-rabbit Fab fragment  Goat IF 1:30 Jackson ImmunoResearch 
Laboratories, USA 
IHC = Immunohistochemistry; WB = Western Blot; IF = Immunofluorescence. 
2.2.2 Biochemicals and chemicals 
Table 3: 
Reagents Supplier 
Absolute ethanol Sigma-Aldrich, Steinheim, Germany 
Agar Applichem, Dermstadt, Germany 
Antibody diluent Zytomed, Berlin, Germany 
β-Marcaptoethanol (98%) Sigma-Aldrich, St. Luis, MO, USA 
Complete Mini Proteinase Inhibitors   Roche Diagnostics, Penzberg, Germany 
Dimethylformamide (DMF) Roth, Karlsruhe, Germany 
Giemsa stain Merck, Dermstadt, Germany 
Glycine Roth, Karlsruhe, Germany 
HIER Citrate Buffer, pH 6 Zytomed Systems, Berlin, Germany 
Hydrogen peroxide (H2O2) Sigma-Aldrich, St. Louis, MO, USA 
Ketamine  CP-Pharma, Burgdorf, Germany 
Laemmli sample buffer Bio-rad, Munich, Germany  
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Litmus paper  Sigma-Aldrich, St. Luis, MO, USA 
May Gruenwald stain Merck, Dermstadt, Germany 
Mayer’s hemalum Merck, Dermstadt, Germany 
Methanol  Merck, Darmstadt, Germany 
Milk powder  Roth, Karlsruhe, Germany 
Mini-PROTEAN pre-cast gel   Bio-rad, Munich, Germany 
Natrium-orthovanadate New England Biolabs, MA, USA  
Non-essential amino acids (NEA) Biochrom, Berlin, Germany 
Paraformaldehyde (PFA)  Sigma-Aldrich, Munich, Germany 
Penicillin-Streptomycin  Biochrom, Berlin, Germany 
Polyvinylidene difluoride (PVDF) 
membrane  
Bio-Rad, Munich, Germany 
Phosphate buffered saline (PBS) Gibco, Life Technologies, Darmstadt, Germany 
Precision Plus Protein Standard  Bio-rad, Munich, Germany 
Rabbit on rodent Alkaline phosphatase 
(AP)-Polymer 
Biocare Medical, Concord, CA, USA 
 
Rodent block M Biocare Medical, Concord, CA, USA 
3R4F research cigarette  Lexington, KY, USA 
Roti-Quick 1 Roth, Karlsruhe, Germany 
Roti-Quick 2 Roth, Karlsruhe, Germany 
Rox reference dye Thermo Scientific, Surrey, UK 
Sodium chloride (NaCl) Braun, Germany 
Sybr Green Thermo Scientific, Surrey, UK 
Sodium dodecyl sulfate (SDS) Biorad Laboratories, Hercules, USA 
Trypan blue Fluka, Steinheim, Germany 
Tris  Roth, Karlsruhe, Germany 
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Trypsin-EDTA Sigma-Aldrich, St. Luis, MO, USA 
Vulcan fast red (VFR) Biocare Medical, Concord, CA, USA 
Xylene Roth, Karlsruhe, Germany 
Xylazine (Proxylaz®) Bela Pharm, Vechta, Germany 
 
2.2.3 Buffers and Solutions  
Table 4: 
Buffer  Composition 
2% Agar Agar- 2 g, Tap water- 100 ml 
Alcoholic eosin 32% Hydrochloric acid- 2 ml, 70% Ethanol- 200 ml  
β-galactosidase staining solution  Citric acid/sodium phosphate- 40 mM (pH 6.0) NaCl- 
150 mM, MgCl2-2 mM, Potassium ferrocyanide- 5 mM, 
Potassium ferricyanide- 5 mM, X-gal-1 mg/ml 
Fixative solution  Fomaldehyde- 2%  and Glutaraldehyde- 0.2% in PBS 
H2O2 solution 1.8% (v/v) 30% H2O2- 6 ml, dH2O-14 ml, Methanol-80 ml 
Ketamine-xylazine solution  Ketamine-14%, Xylazine-3% and NaCl-83% 
Laemmli sample buffer 1X β-mercaptoethanol-100 1 μl, 4X Laemmli buffer-900 μl 
Paraformaldehyde (PFA) 6% PFA- 6 g, PBS- 100 ml 
PBS-tween buffer stock solution 10X dH2O- 1 L, Tween 20- 1ml (=0.1%) 
Ponceau S solution Ponceau S-0.1% (w/v), acetic acid- 5% (v/v) 
Radioimmunoprecipitation assay 
(RIPA) buffer 
NaCl 150 mM, Tris- 10 mM pH 7.2, SDS- 0.1%, Triton 
X- 100%, Deoxycholate- 1%, EDTA- 5 mM 
Running buffer stock solution 5X Tris- 15.1 g, 10% SDS- 50 ml, Glycine- 94 g,  
dH2O- 900 ml 
TBS  buffer 1X 20X TBS- 50 ml, dH2O-950 ml 
Transfer buffer stock solution 20X Methanol- 200 ml, Tris- 2.42 g (20 mM),  
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Glycine- 11.2 g (150 mM), dH2O- 1 L 
Vulcan fast red, VFR  VFR buffer- 2.5 ml, VFR- 1 drop 
 
2.2.4 Instruments and softwares 
Table 5: 
Equipments  Supplier 
Automatic tissue processor TP 1020 Leica, Wetzlar, Germany 
AxioObserver.Z1 inverted microscope Zeiss, Göttingen, Germany 
Axiovision 4.8 software Zeiss, Göttingen, Germany 
Biosystem XA forced maneuver system  Buxco, Wilmington, USA 
Centrifuge apparatus Retina 35R Hettich, Ebersberg, Germany 
Centrifuge apparatus Universal 32R Hettich, Tuttlingen, Germany 
Centrifuge apparatus Minispin Plus Eppendorf, Hamburg, Germany 
Cell counter AC-12 Assistant, Sondheim, Germany 
Chemidoc XRS detection system  Bio-Rad, Munich, Germany 
Computer Assisted Stereological 
Toolbox (newCAST) software 
Visiopharm, Hoersholm, Denmark 
Dakopen Dako, Glostrup, Denmark 
Decloaking chamber Biocare Medical, Concord, CA, USA 
Electrophoresis chamber Bio-rad, Munich, Germany 
Electronic stirrer IKA, Wilmington, USA 
Embedding apparatus Histostar Thermo Scientific, Germany 
FinePointe RC system Buxco, Wilmington, USA 
FlexiVent system SCIREQ Inc, Montreal, Qc, Canada 
GraphPad Prism 5 software  GraphPad Software, La Jolla, USA 
Heating-blocks  Haep Labor Consult, Bovenden, Germany 
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ImageLab 5.0 software Bio-Rad, Munich, Germany 
Imaris 7.6.5 software  Bitplane, Zurich, Switzerland 
Micro dismembrator  Sartorius, Göttingen, Germany 
Microplate autoreader  Perkin Elmer, Germany 
NanoDrop 1000 spectrophotometer Peqlab, Erlangen, Germany 
Nylon meshes   Sefar, Heiden, Switzerland 
Primer3 NCBI, USA 
Olympus BX51 light microscope Olympus, Hamburg, Germany 
Real-Time PCR System  Applied Biosystems, Carlsbad, CA 
Rotary microtome Hyrax M55 Zeiss, München, Germany 
Shandon Cytospin 2 centrifuge  Thermo Scientific Shandon, UK 
Thermal Cycler PTC 200 Bio-rad, Germany 
Thermomixer Eppendorf, Hamburg, Germany 
Trans-blot cassette  Bio-rad, Munich, Germany 
Vortex  IKA, Wilmington, USA 
 
2.2.5 Kits  
Table 6: 
Kits  Supplier 
peqGOLD Total RNA kit Peqlab, Erlangen, Germany 
GeneAmp RNA PCR kit Applied Biosystems, Carlsbad, CA 
β-galactosidase assay kit Cell signaling, Frankfurt, Germany 
Pierce BCA Protein Assay kit  Thermo Scientific, Rockford, IL, USA 
Amersham ECL Prime Detection kit (GE Healthcare, Freiburg, Germany). 
Platinum SYBR Green qPCR SuperMix kit  Applied Biosystems, Darmstadt, Germany 
Vulcan fast red chromogen kit Zytomed, Berlin, Germany 
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2.2.6 Enzymes 
Table 7:  
Enzymes  Supplier 
DNAse 1 Peqlab, Erlangen, Germany 
Dispase  BD Bioscience, San Jose, CA, USA 
MuLV Reverse transcriptase Applied Biosystems, Carlsbad, CA 
Porcine pancreatic elastase (PPE) Sigma-Aldrich, Munich, Germany 
 
2.2.7 Cell Lines 
Table 8: 
Cell lines Supplier 
Mouse lung epithelial cell (LA4) American Type Culture Collection (ATCC), 
Rockville, MD,USA 
  
2.2.8 Cell culture media 
Table 9: 
Medium Supplier 
Dulbecco's Modified Eagle's Medium, DMEM PAA Laboratories, Pasching, Austria 
Ham’s F12K nutrient medium Biochrom, Berlin, Germany 
RPMI 1640 medium   Biochrom, Berlin, Germany 
 
2.2.9 Serum 
Table 10: 
Serum  Supplier 
Fetal bovine serum Gibco, Life Technologies, Darmstadt, Germany 
Bovine serum albumin Thermo Scientific, Rockford, IL, USA 
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2.2.10 siRNA and transfection reagents 
Table 11: 
siRNA/ reagent Supplier 
CARM1-specific siRNA  Qiagen, Hilden, Germany 
AllStars negative control siRNA Qiagen, Hilden, Germany 
HiPerfect transfection reagent Qiagen, Hilden, Germany 
 
2.2.11 Oligodeoxynucleotides/primers 
Primers were designed using Primer3 software (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). 
Table 12: 
Gene Left primer  (5´-3´) Tm Right primer (5´-3´) Tm 
HPRT1 CCTAAGATGAGCGCAAGTTGAA                   59.00 CCACAGGACTAGAACACCTGCTAA 61.84 
CARM1 GTGGGCAGACAGTCCTTCAT                          59.67 GTCCGCTCACTGAACACAGA 59.97 
SIRT1 CCATTAATGAGGAAAGCAATAGGC         58.22 AATACAAGGCTAACACCTTGGG 58.3 
p16 TCGTGAACATGTTGTTGAGGC                        59.4 CTACGTGAACGTTGCCCATC 59.28 
p21 CGGTGTCAGAGTCTAGGGGA                          60.03 AGAGACAACGGCACACTTTG 58.7 
p53 GTCACGCTTCTCCGAAGACT                           59.76 ACAGATCGTCCATGCAGTGAG 60.13 
PCNA CCACATTGGAGATGCTGTTG 57.07 CCGCCTCCTCTTCTTTATCC 57.46 
Ki67 TTGACCGCTCCTTTAGGTATGAA 59.48 GGTATCTTGACCTTCCCCATCA 59.22 
Cyc E1 GAGCTTGAATACCCTAGGACTG 62 CGTCTCTCTGTGGAGCTTATAGAC 65 
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2.2 METHODS 
2.2.1 Animals 
Eight to ten weeks old pathogen-free female C57BL/6 mice were obtained from Charles 
River Laboratories (Sulzfeld, Germany). The CARM1 haploinsufficient mice (232) were 
generously provided from Mark Bedford (University of Texas MD Anderson Cancer Center). 
Briefly, to generate Carm1+/– mice, the Carm1–/– mice was first generated by gene 
targeting. The targeting vector was constructed by introducing a neomycin-resistance (neo) 
cassette which was flanked by short flippase recognition target (frt) sites into an intronic 
region. Two exons coding for 71 amino acid-long fragment (amino acids 117–187) were 
deleted. The deletion of this coding region resulted in a removal of a three-helix segment 
involved in cofactor binding (AdoMet) and formation of Rossmann fold. Using southern blot 
hybridization, the targeted clones were identified. Targeted embryonic stem (ES) cells were 
used to generate chimeric mice. Males with a high contribution of ES cells were crossed with 
Black Swiss females to generate F1 CARM1 haploinsufficient progeny. In our lab, mice were 
maintained on a C57BL/6N background. 
 
Figure 7: Targeted deletion of Carm1 exon. A neo cassette flanked by frt sites was incorporated into the intronic region of 
CARM1 gene. Two Carm1 exons, encoding a segment of the substrate-binding pocket, were floxed. Arrowheads: loxP sites, 
solid boxes: exons, hatched boxes:frt sites, filled arrows:direction of transcription and open arrows: position of PCR primers 
used to generate the arms of the targeting vector construct. 
56 
 
Mice were housed in rooms maintained at constant temperature and humidity with a 12 hour 
light cycle and were allowed to access rodent laboratory chow and water ad libitum. All 
animal experiments were carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The 
protocol was approved by the ethics committee of the regional governmental commission of 
animal protection.  
 
Emphysema was induced by an oropharyngeal application of porcine pancreatic elastase, 
PPE (Sigma-Aldrich) of 80 U/kg body weight in 80 µl volume. Control mice (n= 5-6) received 
80 µl sterile phosphate buffered saline, PBS (Gibco). Wild type mice were analyzed on day 2, 
28, 56 and 161 and CARM1 haploinsufficient mice were analyzed on day 28. The experiment 
was repeated twice. 
 
2.2.2 Lung function measurement  
Mice were anesthetized with ketamine-xylazine combination solution at the following 
proportion: 14% Ketamine, 3% xylazine and 83% NaCl by intraperitoneal (i.p.) application at 
a dosage of 0.1 ml/10 gm body weight of mouse. Once sedated, mice were tracheostomized 
using an 18 gauge cannula. After intubation, mice were connected to a computer-controlled 
Biosystem XA forced maneuvers system and a FinePointe RC system (Buxco) or FlexiVent 
(SCIREQ Inc) to measure lung parameters using a software-generated script. The 
parameters quantified were Forced Expiratory Volume, (FEV), Functional Residual Capacity 
(FRC), Total Lung Capacity (TLC), Tiffeneau-index (FEV0.1:FVC ratio), Dynamic 
compliance/body weight ratio (Cdyn/BW) and tissue elastance (E). The analyzed parameters 
were visible in the software during collection and statistical reporting by treatment group was 
provided immediately after collection. 
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2.2.3 Bronchoalveolar lavage (BAL) collection and quantification  
BAL was obtained to perform total and differential cell counts for inflammatory cell 
recruitment of neutrophils, macrophages and lymphocytes. The lungs were lavaged by 
instilling the lungs with 3 x 0.5 ml aliquots of sterile PBS containing protease inhibitor 
(Roche). For cytospins, cells were spun down at 400 g and resuspended in RPMI 1640 
medium containing 10% (v/v) FBS (both from Gibco). Total cell counts were determined in a 
hemocytometer via Trypan Blue exclusion using the following equation: Total cells/ml= (Total 
cells counted / number of square counted) x dilution factor x 10,000 cells/ml.  
 
For cytospin, a volume containing 30,000 cells loaded in a cytofunnel were centrifuged at 
400 rmp for 6 minutes in a Shandon Cytospin 2 centrifuge apparatus (Thermo Scientific 
Shandon). The cytospun cells were stained for 10 minutes in May Gruenwald’s eosin-
methylene blue solution (Merck). The solution stains the nuclei blue and cytoplasm pinkish-
red. Excess stain was removed by placing the slides in tap water for 2 minutes. 
Subsequently, the slides were incubated in (1:20, vol/vol) Giemsa solution (Merck) 15 
minutes. Giemsa solution is a complex consisting of methylene blue chloride, eosin-
methylene blue and azure II eosinate. It improves the intensity of nuclear staining and 
selectively distinguishes cellular structures. Excess stain was removed by incubating the 
slides in tap water for 2 minutes. Differential cell counts were performed using morphological 
criteria on stained cytospins (200 cells/sample). 
 
2.2.4 Lung fixation  
The lungs were perfused free of blood with PBS through the right ventricle of the heart. The 
right lung was removed for molecular biology studies whereas the left lung was inflated by an 
intratracheal instillation of PBS-buffered 6% paraformaldehyde, PFA (Sigma-Aldrich) at a 
constant pressure of 20 cm fluid column for 10 minutes. For complete fixation, the inflated 
lungs were stored in PFA at 4°C for at least 24 hours. Afterwards, lungs were embedded in 
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paraffin for histological and immunohistochemical analysis. Briefly, the lung was placed into 
20 ml of 2% (w/v) lukewarm agar and allowed to freeze at 4°C for 1 hour. The lung was 
sliced into 2 mm thick sections using a cutting apparatus and thinly overlaid with agar in an 
ice-filled tray. The orientation of lung sections was maintained during the entire cutting 
procedure.  Excess agar was excised once the agar hardened enough. The agar blocks were 
put it in the embedding cassettes and stored in 4% formalin until further processing. 
 
                                                                   
Figure 8: A 20 cm fluid column of PFA (Left) and cutting apparatus for agar block (Right) (Both images adapted from Yildirim 
lab). 
 
2.2.5 Lung tissue processing: Paraffin embedding 
Lungs were embedded in paraffin for histological and immunohistochemical. Briefly, lung 
sections in individual cassettes were placed in an automatic tissue processor (Leica) for 
overnight where they undergo serial dehydration through 70%, 80%, 96% (3x), 100% (3x) 
ethanol. The alcohol was removed by passing the cassettes through Roticlear (2x) (Roth), a 
less toxic alternative product for xylene. This step rendered the tissue clear. Next, the tissues 
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were infiltrated by immersion in liquid paraffin wax to saturate the tissue cavities and cells. 
The lung blocks were embedded again in paraffin in a steel mould and cooled on the cold 
plate section the embedding apparatus (Thermo Scientific) for 30 minutes for complete 
solidification before sectioning.  
       
Figure 9: Automatic tissue processor (Left) (Adopted from http://www.leicabiosystems.com) and embedding apparatus (right) 
(Adapted from Yildirim Lab).   
 
2.2.6 Lung tissue sectioning  
Before cutting the blocks, they were placed at 4°C for overnight.  Lung tissues were manually 
sectioned using a motorized rotary microtome (Zeiss).  Paraffin blocks were place in the cool 
block section of a microtome. The cool block maintains temperature at 4°C. The microtome 
tank was filled with distilled water and the water flow speed was set between 5 and 6 that 
made the flow suitable for the cut sections to transfer into the water tank. The angle between 
the paraffin block and the microtome knife was set at 11 degree angle. To access the lung 
tissue, the blocks were first trimmed by cutting several 10 µm thick sections at speed of 80 
mm/sec. Blocks were cut into 3 µm thick sections at the speed of 50 mm/sec. the sections 
were transferred using a non-charged glass slide into a water bath. There the sections were 
stretched in hot demineralized water for few seconds. The water temperature was about 10 
degrees below the melting point of paraffin (approximately 45°C). Charged slides were used 
to collect tissue section as the positively charged coating attached to the tissue through 
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negative charges in the tissue. The slides with sections were placed on a heating plate set at 
45°C to dry the slides for at least an hour to ensure adhesion. To evaporate the water and to 
fix the sections on glass, all slides were kept in incubator at 37°C overnight. 
 
2.2.7 Histological staining: Hematoxylin and eosin (H&E) staining 
The H&E staining method involves application of hemalum, which is a complex formed from 
aluminum ions and hematein, an oxidation product of haematoxylin. Hemalum colors nuclei 
of cells blue. The nuclear staining is followed by counterstaining with an aqueous or alcoholic 
solution of eosin, which colors other eosinophilic structures in various shades of red, pink 
and orange. In the staining protocol, xylene was used as a clearing agent. It is miscible with 
the embedding medium (paraffin) and the dehydrant (ethanol). Xylene was used at two 
different stages in H&E staining a) Deparaffinization- removal of paraffin and b) Clearing- 
displacement of alcohol from the tissue sections with the clearing agent before cover-slipping 
with mounting media. Firstly, the tissue sections were incubated in xylene for 5 minutes (2x). 
The sections were passed through an ethanol gradient (ethanol 100% 2x, 90%, 80% and 
lastly 70%) for 1 minute in each followed by a quick rinse with distilled water to remove 
ethanol. To stain the nuclei, the tissue sections were stained in Mayer´s Hemalaum (Merck) 
for 5 minutes and rinsed off in running water to get blue in colour. Slides were then stained 
were dipped in 0,3% HCl-Alcohol (prepared with 70% ethanol) for few seconds to remove 
excess stain and define nuclei following hematoxylin staining. The step is called the 
differentiation. The sections were washed in running tap water for 8 minutes and then quickly 
rinsed in distilled water. Slides were then stained with alcoholic eosin solution for 5 minutes 
and rinsed off with running water to remove extra staining. A dehydration step was carried 
out by quickly rinsing the sections in gradient of ethanol (70%, 80%, 90% for few seconds) 
and in 100% ethanol for 2 minutes (2x). Finally, the slides were cleared in 2 changes of 
xylene, 5 minutes each. Afterwards tissue sections were manually cover-slipped with 24 x 50 
mm cover glasses.  
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2.2.8 Immunohistochemistry  
The paraffin embedded lung sections (3 μm) were deparaffinized in xylene and rehydrated in 
alcohol. The tissue was treated with 1.8% (v/v) H2O2 solution (Sigma-Aldrich) for 20 minutes 
to block endogenous peroxidase. Heat induced epitope retrieval  was performed in HIER 
Citrate Buffer (pH 6.0, Zytomed Systems) in a Decloaking chamber (Biocare Medical) set for 
30 min at 125°C and 10 min at 90°C. After cooling down, the slides were rinsed in washing 
buffer, TBS (Zytomed Systems) for 2 minutes each (3x). Nonspecific binding was inhibited 
with a blocking antibody (Biocare Medical). Tissue sections were incubated overnight at 4°C 
with primary antibodies against CARM1 (1:150, Abcam), SIRT1 (1:100, Millipore), p16 (1:50, 
Santa Cruz) and β-galactosidase (1:50, Life Technologies). For negative controls, a rabbit 
IgG was used instead of primary antibody.  The next day following washing steps, tissue 
sections were incubated afterwards with an alkaline phosphatase-labeled secondary 
antibody (Biocare Medical) for 1 hour at room temperature. Signals were amplified by a 
chromogen substrate Vulcan fast red (Biocare Medical). VFR solution was prepared right 
before incubation (as it is not very stable) by adding 1 drop of Vulcan Fast Red in 2.5 ml of 
VFR buffer.  Tissues were counterstained with hematoxylin for 3 minutes, rinsed in water and 
incubated in washing buffer for 5 minutes. The sections were dehydrated in ethanol (96% for 
1 minute), 100% for 2 minutes (2x) and finally in xylene for 5 minutes (2x). 
 
2.2.9 Immunofluorescence staining 
Lung sections were deparaffinized, rehydrated and pressure-cooked in citrate buffer followed 
by peroxide treatment. After incubation with blocking antibody, the tissue sections were 
incubated with rabbit polyclonal antibody against Pro-surfactant Protein C (1:100 SP-C, 
Millipore), CARM1 or SIRT1 followed by 1 hour incubation with donkey anti-rabbit IgG Alexa 
Fluor 488 labeled secondary antibody (1:250, Invitrogen, Darmstadt, Germany). For nuclear 
staining, the sections were incubated with 4′,6-diamidino-2-phenylindole (DAPI 1:2000, 
Sigma) in PBS for 1 minute at room temperature.  
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For the detection of two unlabeled primary antibodies from the same host species (rabbit) we 
used the following protocol, whereas all incubation steps are at room temperature: the 
deparaffinized lung sections were blocked with 5% BSA in PBS for 30 min. Then the lung 
slices were incubated with the primary antibody (Surfactant Protein-C, SP-C) for 2 hours, 
washed in PBS and then the first antibody was converted into a different host by incubation 
with a monovalent goat-anti-rabbit Fab fragment (Jackson ImmunoResearch Laboratories, 
1:30 in PBS) for 2 hours. The masked antibody complexes were fixed with 4% PFA/PBS for 
2 min and subsequently incubated with a donkey anti-goat IgG Alexa Fluor 568 secondary 
antibody (1:250, Invitrogen, Darmstadt, Germany) for 1 hour. Finally, the lung sections were 
stained with the rabbit CARM1 or SIRT1 antibodies for 2 hours, washed in PBS, and stained 
with the secondary donkey-anti-rabbit IgG Alexa Fluor 488 antibody for 1 hour. 
 
2.2.10 Quantitative stereological analysis 
2.2.10.1 Quantification of airspace enlargement  
An unbiased design-based stereology was used to analyze sections using an Olympus BX51 
light microscope equipped with the new Computer Assisted Stereological Toolbox 
(newCAST, Visiopharm) on HE-stained lung tissue slides as previously described (139). 
Briefly, a statistical estimate of air space enlargement (the mean free distance in the air 
spaces) was assessed by quantifying mean linear chord length (Lm) on 30 systemic random 
fields of view per lung. A line grid was superimposed on lung section images taken using the 
20x objective. Intercepts of lines with alveolar septa and points hitting air space were 
counted to calculate mean chord length, Lm as a measurement of airspace enlargement 
applying the formula: Lm = ∑Pair x L(p) / ∑Isepta X 0.5, where, Pair are the points of the grid 
hitting air spaces referring to the volume of air space, L(p) is the line length per test point 
(99.3 µm as we measured) and Isepta is the sum of intercepts of alveolar septa with grid lines 
referring to the alveolar surface area.  
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Figure 10: A grid with points and lines was superimposed on each lung tissue section where points (black points on orange 
line segments) representing alveolar air space volume (Σ Pair) were counted. Additionally, the total number of intercepts of 
the line segments (orange lines) intercepting the alveolar septal surfaces (Σ Isepta) were counted. This image is a screenshot 
of CAST system. 
 
2.2.10.2 Quantification of CARM1 or SIRT1 positive alveolar epithelial cells 
To quantify the percentage of CARM1 positive alveolar epithelial cells with newCAST 
(Visiopharm), 30 systemic random fields of view per lung was chosen. A frame grid was 
superimposed on lung section images taken using the 40x objective. Within the frame, 
alveolar epithelial cells either positive or negative for CARM1 staining were counted and the 
percentage of CARM1 positive alveolar epithelial cells was calculated.  
 
Same method was applied to calculate the percentage of SIRT1 positive alveolar epithelial 
cells in the lung. 
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2.2.10.3 Quantification p16 positive alveolar epithelial cells 
To quantify p16 positive cells a semi-quantitative manual scoring system was applied. Each 
lung tissue stained with p16 antibody was scored on a scale from 0–5 where 0 = no positive 
cells, 1= lowest, 2= moderate, 3= considerable, 4= marked and 5 = highest frequency of p16 
positive cells.  
 
2.2.10.4 Quantification of SP-C positive alveolar epithelial cells 
Images of SP-C stained lung sections were taken with an AxioObserver.Z1 inverted 
microscope (Zeiss) using a Plan-Apochromat 20x/0.8 M27 objective. The automated 
microscopy system was driven by Axiovision 4.8 (Zeiss). For each condition 5 images were 
taken. The acquired data sets were imported into Imaris 7.6.5 software (Bitplane). Then, the 
spot detection algorithm of the Imaris software was used to assign a spot for each 
fluorescent intensity of DAPI stained nuclei and Pro-SPC stained cells. Finally, the number of 
spots was read out by the Imaris’ statistics module.   
 
2.2.11 Quantitative real time RT-PCR 
2.2.11.1 Homogenization and lysis  
a) Tissue 
The right lung tissue was homogenized using a micro dismembrator (Sartorius). Briefly, 
frozen tissues in cryogenic gyrotubes containing grinding balls were placed in a pre-cooled 
Teflon shaking device and shaken at 3000 rpm for 1 minute. A major amount of powder was 
collected and frozen at -80°C for later protein isolation. Roti-Quick 1 (Roth), a tissue lysis 
buffer was added to the remaining tissue powder and vortexed till the powder dissolved in 
suspension. The liquid was used for immediate RNA extraction or frozen at -80°C for later 
extraction.  A Phenol-Chloroform extraction step was carried out to eliminate proteins. Briefly, 
following the addition of Roti-Quick 2 solution (Roth) to each homogenized sample solution, 
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the tubes were incubated on ice for 10 minutes and vortexed every 2 mintues. The samples 
were then centrifuged at 13000 rpm at 4°C for 15 minutes.  
 
b) ATII-like LA-4 monolayer cells  
For lysis of cells grown in monolayer, the culture medium was completely aspirated. The 
cells were twice washed with PBS. RNA Lysis Buffer T (Peqlab) was added to the cells and 
the lysate was transferred in a DNA Removing Column (Peqlab) placed in a 2.0 ml Collection 
Tube and centrifuged at 12000 rcf for 1 min at room temperature. The flow-through lysate 
was used for RNA extraction. 
 
2.2.11.2 RNA isolation and concentration determination 
The total RNA was isolated from lung tissue homogenate or cell lysate using peqGOLD Total 
RNA kit (Peqlab, Erlangen, Germany) according to the manufacturer’s instructions and all 
steps were performed at room temperature. Briefly, an equal volume of 70% ethanol was 
added to it the supernatant got from tissue or cells and vortexed. A volume of 750 μl solution 
was taken in a PerfectBind RNA-binding column placed in collection tube and was 
centrifuged at 10000 rcf for 1 minute. This step was repeated using the remaining solution. 
The RNA-binding columns were washed with RNA Wash buffer 1 and centrifuged at 10000 
rcf for 15 seconds. To remove DNA a DNAse digestion solution was applied onto the 
membrane of RNA-binding columns, incubated for 15 minutes and then washed again with 
RNA wash buffer 1. Following 5 minute incubation, the tubes were centrifuged at 10000 rcf 
for 15 seconds. The columns were washed with RNA Wash Buffer 2 and centrifuged for 15 
sec at 10000 rcf. To completely remove ethanol, the RNA column placed in collection tube 
was centrifuged for 2 min at 10000 rcf. For eluting the extracted RNA, sterile RNAse-free 
dH2O was added directly onto the membrane of the columns and centrifuged for 1 min at 
5000 rcf. The eluted RNA was either taken for concentration determination or kept at -80°C 
for long term storage. 
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The RNA concentration was determined using the NanoDrop 1000 (Peqlab). The optimum 
range of the NanoDrop spectrophotometer is 2-3700 ng/μl. A volume of 1 μl of 1 μl of sample 
RNA was pipetted onto the pedestal and measured. A blank test was performed with sterile 
RNase-free water before measuring the RNA concentration. The purity was determined by 
calculating the ratio of absorbance at 260 nm and 280 nm. Volume needed for 1 μg of RNA 
was calculated from the determined concentration for cDNA preparation.  
 
2.2.11.3 cDNA synthesis  
It is the reverse transcriptase–mediated synthesis of single-stranded DNA (complementary 
DNA or cDNA) using single-stranded RNA as template. A volume equivalent to 1 μg of RNA 
was added to DNAse-RNAse free water to prepare a total of 20 μl volume and denatured at 
70°C for 10 minutes on a heating block (Haep Labor Consult). A master mix of 20 μl was 
prepared from the GeneAmp RNA PCR kit (Applied Biosystems) as following: 
Table 13: 
 Reagents Volume  
10x PCR Buffer II 
25mM MgCl2 
10mM each type of  dNTPs 
50μM Random Hexamers:          
ddH2O                                   
10U RNase Inhibitor:                
50U MuLV Reverse Transcriptase        
4.0 μl  
8.0 μl 
2.0 μl 
2.0 μl 
1.0 μl  
1.0 μl 
2.0 μl 
 
The 10x PCR Buffer II provided the optimal pH and ionic strength for PCR amplification. A 
separate MgCl2 solution was used together with the buffer to optimize the magnesium ion 
concentration to achieve optimal PCR amplification with any specific set of primers and DNA 
67 
 
template. The dNTPs consisted of dATP, dCTP, dGTP, and dTTP. Random Hexamers used 
were short oligodeoxyribonucleotides of random sequence [d(N)6] that annealed to random 
complementary sites on a target RNA to serve as primers for DNA synthesis by reverse 
transcriptase. RNase Inhibitor (ribonuclease inhibitor) was a 50 kDa recombinant enzyme 
used to inhibit RNase activity to prevent the degradation of RNA template. It does not contain 
DNase or endonuclease activity. MuLV (Murine Leukemia Virus) reverse transcriptase in the 
master mix was a recombinant RNA-dependent DNA polymerase that used single-stranded 
RNA as a template in the presence of a primer to synthesize a complementary DNA (cDNA) 
strand. The reverse transcription was carried out in PCR cycler (Bio-rad) following the 
thermal conditions in a thermal cycler: 
 10 min at 20°C to extend random primers or oligo (dT) primers; without the incubation   
 primers may dissociate from the template at higher temperature; 
 75 min at 43°C for reverse transcription;  
 5 min at 99°C to terminate the reaction.  
The cDNA was cooled down to 4 °C, diluted with ddH2O to a final volume of 100 μl and 
stored at -20°C. 
 
2.2.11.4 Amplification of cDNA  
Quantitative real-time PCR was performed using Platinum SYBR Green qPCR SuperMix 
(Applied Biosystems, Darmstadt, Germany) on a StepOnePlus™ 96 well Real-Time PCR 
System (Applied Biosystems, Carlsbad, CA). HPRT1 (Hypoxanthine-guanine phospho-
ribosyltransferase) was used as a reference housekeeping gene in all qRT-PCR reactions. 
The mRNA expression of target genes was determined in comparison to HPRT1. Primers 
used are listed in Table 10. Relative gene expression presented as 2ΔCT (ΔCt = Ctreference - 
Cttarget) and relative change to control as 2
ΔΔCt (ΔΔCt = ΔCtcontrol - ΔCttreated). Primers were 
generated using NCBI Primer-BLAST software. For PCR master mix, the following reagents 
were added to cDNA-Template 2 µl to a total volume of 25 µl: 
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Table 14: 
Reagents Volume  
Sybr Green Buffer 
MgCl2 (50mM) 
Primer mix (forward and reverse)  
dH2O 
13 µl 
1 µl 
1 µl (0.5 µl +0.5 µl) 
8 µl 
 
Sybr Green Buffer mix (Thermo Scientific) contained SYBR Green I fluorescent dye, 
Platinum Taq DNA polymerase, Magnesium ion, uracil-DNA glycosylase (UDG), proprietary 
stabilizers, and deoxyribonucleotide triphosphates (dNTPs). SYBR Green I was a fluorescent 
dye that binded directly to double-stranded DNA (dsDNA). The primer pairs used in the 
reaction were 20-22 base pair long with melting temperature between 57 to 60°C and with 
40-60% GC content. The maximum single nucleotide repeat was 4 base pair long. A 
negative control that contained all reagents but not the template DNA was used as no 
template control or NTC. The PCR was performed in Step One plus PCR system using the 
following thermal profile: 
Table 15: 
Holding/pre-incubation Stage: Step 1:  2 min for 50 °C  
Step 2: 5 min for 95 °C 
Cycling Stages (44 cycles): Step 1:  5 sec for 95 °C   
Step 2:  5 sec for 59 °C   
Step 3:  30 sec for 72 °C 
Melt Curve Stage: 
 
Step 1: 15 sec for 95 °C   
Step 2:  1 min for 60 °C 
Step 3: 15 sec for 95 °C 
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2.2.12 Western blot 
2.2.12.1 Protein isolation and concentration determination 
Protein extraction from lung tissue and cell lines was performed using RIPA buffer containing 
1:25 Complete Mini Proteinase Inhibitors (Roche) and 1:100 of 100mM Natrium-
orthovanadat (New England Biolabs) and shortly vortexed time to time. The samples were 
centrifuged for 15 min at 4°C at 13000 rpm. The supernatant was taken to measure protein 
concentration.  
 
A volume of 10 µl from of each standard or supernatant of unknown sample replicate was 
pipetted into a 96-well microplate. A total of 200µl substrate solution (reagent A: reagent B = 
50:1) from Pierce BCA Protein Assay kit (Thermo Scientific) was added to it. The assay uses 
the formulation based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantitation of total protein. BCA is a weak acid composed of two carboxylated quinoline 
rings. In BCA assay, two molecules of bicinchoninic acid chelate a single Cu+ ion, forming a 
purple water-soluble complex. Reagent A contained sodium carbonate, sodium bicarbonate, 
BCA and sodium tartrate in 0.1M sodium hydroxide while BCA Reagent B contained 4% 
cupric sulfate. The protein concentrations were determined using a reference protein such as 
bovine serum albumin (BSA) as a standard. A series of dilutions of known concentration 
were prepared from the BSA and assayed alongside the protein sample of unknown 
concentration before the concentration of each unknown is determined based on the 
standard curve. The plate was incubated at 37°C for 45 minutes for reactions to take place. 
In the first reaction, copper was chelated by protein and formed a light blue complex. 
Secondly, the BCA reacted with the reduced (cuprous) cation formed in step one and 
resulted in an intense purple-colored product from the chelation of two molecules of BCA 
with one cuprous ion. The BCA/copper complex showed a linear absorbance at 570 nm with 
increasing protein concentrations measured using a microplate reader (Perkin Elmer).  
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2.2.12.2 SDS-PAGE run and blotting 
A volume of 20 µg of protein was mixed with Laemmli loading buffer (Biorad) and was boiled 
at 95°C for 10 minutes at 300 rpm on Thermomixer (Eppendorf). Samples were loaded in a 
10% or 12% Mini-PROTEAN pre-cast gel (Biorad) and run at constant electric current (about 
40mA per chamber) and at 120V for 1 hour. A ladder, Precision Plus Protein Standard 
(Biorad) used as a molecular weight marker for identification of protein of interest.  
 
To transfer/blot the gel was assembled in a sandwich in a Transblot cassette (Bio-Rad) and 
run in 1x transfer buffer for 1 hour at 100V. Following the transfer, the membrane was 
incubated in blocking buffer (5% milk solution in PBS) for 1 hour at room temperature to 
block unspecific binding sites. After blocking, the membrane was incubated with antibodies 
against CARM1 (1:750, Abcam), anti-phospho-CARM1 (1:500, Abnova), anti-SIRT1 (1:1000, 
Millipore), anti-p16 (1:200, Santa Cruz), anti-p21 (1:200, Santa Cruz) and anti-T1α (1:4000, 
R&D, Minneapolis, Minnesota, USA) in 1:5 diluted blocking buffer for overnight at 4°C. Next, 
the membrane was incubated with a horseradish peroxidase (HRP)-linked anti-rabbit 
secondary antibody for 1 hour at room temp. An anti-β-actin antibody (Sigma-Aldrich) was 
used as loading control.  
 
2.2.12.3 Signal development and quantification 
The signal from protein bands were visualized by developing the membrane using 
Amersham ECL Prime Western Blotting Detection Reagents (GE Healthcare). The two 
detection reagents from the kit when mixed in 1:1 proportion functioned as the substrate for 
horseradish peroxidase (HRP) linked onto the secondary antibody. The signal was detected 
on a Chemidoc XRS system (Bio-Rad). A densitometric analysis was performed on the 
developed signals using ImageLab software (Bio-Rad) and the value was normalized to that 
of β-actin.  
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2.2.13 Cell culture 
2.2.13.1 Condition and maintenance 
The mouse lung epithelial cell line LA-4 (ATCC) which exhibits an alveolar epithelial type II 
like phenotype (275) and adherent in nature was cultured in Ham’s F12K medium (Biochrom) 
containing stable glutamine with 1.176 g/l NaHCO3 and with 10 mg/l phenol red. The medium 
was further supplemented with 15% fetal calf serum (Gibco), 1% non-essential amino acids 
(Biochrom), 1% Penicillin-Streptomycin (Biochrom). The cells were maintained in 75 
cm2 flasks at 37°C incubator and subcultured in a ratio of 1:3, twice per week. The cells were 
used for siRNA transfection, wound healing assay and beta-galactosidase assay and 
cigarette smoke extract treatment.  
 
2.2.13.2 siRNA transafection 
For siRNA application, 4x104 cells in 500 µl per well were seeded in 24-well plates 24 hours 
prior to transfection. 50 nM CARM1-specific siRNA (siCARM1-2 and siCARM1-5) (Qiagen) 
was mixed with 4.5 µl HiPerFect transfection reagent (1:22) (Qiagen) in a serum-free 
medium mixed thoroughly by vortexing and incubated for 10 min at room temperature to 
allow the formation of transfection complexes. HiPerFect is a mixture of cationic and neutral 
lipids that enables effective siRNA uptake and efficient release of siRNA inside cells. AllStars 
Negative Control siRNA (Qiagen) was used as the scrambled (Scr) siRNA. This siRNA has 
no homology to any known mammalian gene. Non-transfected cells were taken as control. 
The siRNA/HiPerfect complex was added in a drop-wise manner onto the cells and the plate 
was gently swirled to ensure uniform distribution of the transfection complexes. The cells 
were incubated at 37°C under their normal growth conditions. The incubation was for 48 
hours to allow an effective knockdown of CARM1 expression. The medium was changed as 
required to avoid cytotoxicity from dead cells. 
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2.2.13.3 Wound healing assay 
The wound healing assay allows studying cell migration and cell proliferation. The assay is 
compatible with adherent cells. In order to perform a wound healing assay, a scratch wound 
was induced by applying a scratch using a 200 µl pipette tip after 48 hours of siRNA 
transfection. While scratching the pipette tip was kept under an angle of around 30 degree. 
Images of the wound were taken after 0 and 16 hours after scratch application. The 
percentage of gap closure was determined by analyzing a defined area of the wound area 
using Axiovision software (Zeiss).  
 
2.2.13.4 Senescence-associated β-galactosidase (SA- β-gal) Staining 
The staining was performed using a kit (Cell signaling) designed to detect β-galactosidase 
activity at pH 6, a known feature of senescent cells not found in pre-senescent,  quiescent or 
immortal cells. The assay was carried out after 48 hours of transfection with siCARM1-2 or 5 
or scrambled siRNA. Cells treated with 100 µM H2O2 (Sigma-Aldrich) for 1 hours were taken 
as positive control. Low concentration of H2O2 is a known inducer of senescence (276). Cells 
in each well of a 24-well plate were washed with PBS. Cell samples were fixed for 10 
minutes at room temperature with a fixative solution. An amount of 20 mg of 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-gal) powder was dissolved in 1 mL DMF (Roth) to 
prepare a 20X (20 mg/ml) stock solution. The cells were incubated with β-galactosidase 
staining solution at 37°C overnight in a dry incubator (no CO2). While the solution was still on 
the plate, the senescent cells were identified by a light microscope as blue or bluish green 
stained cells. For quantification, a total of 300 cells were counted in 10 random fields per well 
to determine the percentage of SA- β-gal positive cells. 
 
2.2.13.5 Preparation of cigarette smoke extract 
Research grade cigarettes 3R4F were obtained from the Kentucky Tobacco Research and 
Development Center at the University of Kentucky. Cigarette smoke extract (CSE) was 
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prepared by bubbling smoke from three cigarettes into 30 ml serum-free media at a rate of 1 
cigarette per 5 minutes. This stock was considered as 100% CSE extract (155). CSE was 
freshly prepared for each experiment and immediately diluted to 5% with culture medium 
Ham’s F12K medium (Biochrom) supplemented with 15% FBS. 
 
2.2.14 Alveolar epithelial type II cell isolation and culture  
Primary mouse ATII cell isolation was performed as described previously (278). In brief, 
mouse lungs were lavaged with 500 µl sterile PBS twice and flushed through the right heart 
with 0.9% NaCl solution. Lungs were inflated with Dispase (BD Bioscience, San Jose, CA, 
USA) and incubated in Dispase (BD Bioscience) for 45 min at room temperature. 
Subsequently lungs were minced and filtered through 100 µm, 20 µm and 10 μm nylon 
meshes (Sefar) and centrifuged at 200 g for 10 minutes. The cell pellet was resuspended in 
DMEM cell culture medium (Sigma-Aldrich). Negative selection for macrophages and 
lymphocytes was performed with antibodies against CD45 and CD16/32 (both BD 
Bioscience). Non-adherent cells were collected and negative selection was performed for 
fibroblasts by adherence for 25 minutes on cell culture dishes. Cell purity was assessed by 
immunofluorescence staining for pro SP-C, panCK, T1α, CD45, CD31 and αSMA. Cells were 
resuspended in DMEM containing 10% FCS, 2 mM l-glutamine, 100 U/ml penicillin, and 100 
g/ml streptomycin, 3.6 mg/ml glucose, and 10 mM HEPES (PAA Laboratories) and cultured 
up to 5 days in a humidified atmosphere of 5% CO2 at 37°C with a medium change at every 
other day. 
 
2.2.15 Statistical analysis 
Mean values ± SD are given unless stated otherwise. Student’s unpaired t-test was used to 
compare two groups, and one-way ANOVA following Bonferroni post-test was used for 
studies with more than two groups, if equal variances and normal distribution was given. 
Analyses were conducted using Prism 5 software (GraphPad). 
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3. RESULTS  
 
3.1 Progressive Lung Emphysema Development in Mice Exposed to 
Porcine Pancreatic Elastase      
To investigate the underlying mechanism of emphysema development and progression, we 
first established a mouse model of emphysema using the porcine pancreatic elastase (PPE). 
Elastase is a well-established tool as it induces irreversible changes in lung structure and 
function (139, 140). Emphysema was induced in wild type C57BL/6 mice via oropharyngeal 
application of porcine pancreatic elastase (PPE) of 80 U/kg body weight in 80 µl volume and 
analyzed on day 2, 28, 56 and 161.  
 
3.1.1 Analysis of lung function              
The pathological changes were monitored using pulmonary function tests. First significant 
signs of emphysema became detectable by an increased forced vital capacity (FVC) at day 2 
(Figure 11A). Significant increases in forced residual capacity (FRC), total lung capacity 
(TLC) as well as in dynamic compliance (Cdyn) represented a time dependent progressive 
emphysematous phenotype after elastase application (Figure 11B-D). In addition, a decrease 
in Tiffeneau index (defined by the ratio of forced expiratory volume of 0.1 seconds (FEV0.1) 
to FVC) and in elastance (E) until day 161 further confirmed further confirmed elastase-
induced emphysema progression in mice (Figure 11E-F).  
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Figure 11. Analysis of elastase-induced impairment of lung function. Pulmonary function tests (A) Forced Expiratory 
Volume, FVC (B) Functional Residual Capacity, FRC (C) Total Lung Capacity, TLC (D) Dynamic compliance/body weight 
ratio (Cdyn/BW) (E) Tiffeneau-index, FEV0.1/FVC measured with Buxco forced maneuvers system and (F) Tissue elastance 
measured with flexiVent by SCIREQ, *p<0.05, **p<0.01, ***p<0.001, 1-way ANOVA followed by Bonferroni post-test, PBS vs. 
elastase-treated animals. Data presented are mean ± SD. The experiments were repeated twice (n=5-6). 
 
3.1.2 Increased airspace enlargement                
To confirm that lung function impairment accompanied with early inflammation in BAL were 
an outcome of lung architecture destruction, next we analyzed lung histology. Hematoxylin 
and Eosin (H&E) stained lung tissue sections revealed a continuous progression of 
emphysema in elastase-treated mice compared to control mice (Figure 12A). As a direct 
measure of emphysema severity, the airspace enlargement was quantified by a quantitative 
morphometry of mean chord length (Lm) using computer assisted stereology toolbox, 
newCAST system (Visiopharm) (Figure 12B). The mean chord length (Lm) indeed confirmed 
a time dependent enhancement of airspace which directly correlated with a significant 
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increase in dynamic lung compliance following elastase treatment compared to PBS-treated 
animals (Figure 12C).  
 
Figure 12. Stereological analysis of elastase induced emphysema progression. (A) Representative histological images 
from H&E stained lung sections. Scale bar: 200 μm, (B) Mean chord length (Lm) quantified by stereological analysis system, 
newCAST to determine airspace enlargement, (C) Positive correlation between dynamic compliance and Lm, *p<0.05, 
**p<0.01, ***p<0.001, 1-way ANOVA followed by Bonferroni post-test, PBS vs. elastase-treated animals. Data presented are 
mean ± SD. The experiments were repeated twice (n=5-6). 
 
3.1.3 Analysis of  bronchoalveolar lavage (BAL) cells          
Next, we examined the inflammatory cell profile by performing bronchoalveolar lavage of 
elastase-treated and PBS-treated mouse lungs. Mice that received elastase showed 
increased total cell counts in bronchoalveolar lavage (BAL) fluid on days 2 to 28 (Figure 
13A), originating mainly from significant increases of macrophages (Figure 13B). Neutrophil 
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levels substantially significant on day 2 only, while lymphocyte counts were elevated from 
days 7 to 21 (Figures 13C and D, respectively). No signs of inflammation could be detected 
in BAL fluid on days 56 or 161. Interestingly, we could not observe lung tissue inflammation 
at any time suggesting that emphysema progression at later time points was inflammation-
independent.  
Taken together, the data demonstrated that a single application of elastase induced 
progressive pulmonary emphysema in mice as evident by the time dependent lung function 
decline, early inflammatory response and gradual airspace enlargement. 
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Figure 13. Characterization of elastase induced emphysema mouse model. Mice were lavaged with 2x 500 µl PBS. (A) 
Total inflammatory cell counts (B) Number of macrophage, (C) Neutrophils and (D) Lymphocytes, *p<0.05, **p<0.01, 
***p<0.001, 1-way ANOVA followed by Bonferroni post-test, PBS vs. elastase-treated animals. Data presented are mean ± 
SD. The experiments were repeated twice (n=5-6).    
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3.2 Reduced CARM1 Expression and Activity in Emphysematous Lungs 
3.2.1 CARM1 downreglation in mouse lung homogenate                
There is evidence that the CARM1–/– neonates are unable to inflate the lung with air due to 
an abnormal alveolar air space demonstrating the involevement of CARM1 in lung 
morphogenesis (232). Besides, CARM1 is also required for proper regulation of proliferation 
and differentiation of alveolar epithelial cells during lung development (251). These crucial 
reports drove us to assess the expression of CARM1 in the elastase-treated emphysematous 
lungs. We noticed a significant downregulation of CARM1 at mRNA level starting from day 
28 (*p<0.05). The expression level showed further decrease till day 161 (**p<0.001) 
compared to time matched PBS-treated animals (Figure 14).  
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Figure 14. Downregulation of CARM1 expression in emphysematous mouse lung. RNA extracted from whole lung 
homogenate. Reverse-transcribed cDNA amplified by quantitative real time PCR (qRT-PCR). CARM1 expression at mRNA 
level in elastase-treated mouse lung compared to PBS treated animals at day 2, 28, 56 and 161, *p<0.05, **p<0.01, 
student’s t-test, PBS vs. elastase treated animals. Data presented are mean ± SD. The experiments were repeated twice 
(n=5-6). 
 
3.2.2 Reduction of CARM1 positive alveolar epithelial cells                                     
Next, we attempted to identify the cell type that reduces the expression of CARM1 in the 
emphysematous lung. To address this question, we performed immunohistochemistry using 
antibody against CARM1 (Figure 15A) and quantified the CARM1-stained lung sections 
using the newCAST system. 
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Figure 15. Elastase treatment reduced CARM1 staining in alveolar epithelial cells. (A) Representative images of 
immmunohistochemistry against CARM1 antibody (1:150). Red arrow: positive staining, black arrow: negative staining. Scale 
bar: 20 µm, (B) Quantification of CARM1 positive alveolar epithelial cells by newCAST stereology system. (C) 
Representative images from immunofluorescence double staining against CARM1 (1:150) and ATII-specific SP-C (1:100) 
antibodies. Green: SP-C positive ATII cells, Red: CARM1 positive cells, Yellow (merged): CARM1 and SP-C double positive 
ATII cells. Scale bar: 10 µm, **p<0.01, student’s t-test, PBS vs. elastase treated animals. Data mean ± SD. Experiments 
were repeated twice (n=5-6). 
 
Quantification revealed a significantly reduced percentage of CARM1 positive alveolar 
epithelial cells at day 28 and day 56 (**p<0.01) (Figure 15B). In addition, we detected that at 
day 161, PBS-treated animals showed reduced CARM1 positive SP-C cells, which we 
speculated as an aging effect in these mice. We did not observe any difference for airway 
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epithelial cells in elastase-treated mice compared to PBS-treated animals. Furthermore, to 
confirm that CARM1 was indeed expressed in ATII cells, we conducted a double staining for 
CARM1 and alveolar epithelial cell type II (ATII) marker SP-C and clearly showed that ATII 
cells lost CARM1 staining following elastase treatment (Figure 15C).  
 
3.2.3 Elevation of CARM1 phosphorylation              
Post-translational modification acts as a molecular switch for controlling CARM1 enzymatic 
activity as evident by phosphorylation at a specific serine residue inactivating CARM1 (245). 
Therefore, we analyzed the levels of of phosphorylated CARM1 compared to unmodified 
native CARM1 levels in the lung homogenate of wild type and elastase-treated mice using  
western blot. 
 
Figure 16. Effect of elastase on CARM1 phosphorylation. (A) Representative western blot for levels of phospho-CARM1 
in lung homogenate. β-actin was used as loading control. The size of each band is indicated on the right. (B) Densitometric 
analysis of western blot for phopspho-CARM1,*p<0.05, **p<0.01, student’s t-test, PBS vs. elastase-treated animals. Data 
presented are mean ± SD. The experiments were repeated twice (n=5-6). 
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We observed an age-dependent increase in phosphorylation of CARM1 at day 161 in PBS-
treated animals. Furthermore, following elastase treatment, we detected a significant 
increase in phospho-CARM1 levels at day 161 compared to day 28 and day 56 (Figure 16A-
B) indicating that the effect of elastase on CARM1 phosphorylation occurs only at later time 
points. However, we did not observe a regulation of CARM1 protein expression among 
different time points (Figure 16C).  
Taken together, these data demonstrated that emphysema progression is associated with a 
downregulation of CARM1 expression in lung alveolar epithelial cells and a reduction of 
global CARM1 activity in lung.  
 
3.3 CARM1 Haploinsufficiency Leading to Enhanced Elastase-induced 
Emphysema in Mouse Lungs                   
3.3.1 CARM1 haploinsufficient mice showed significantly reduced level of CARM1 
As complete loss of CARM1 exhibits neonatal lethality, we therefore considered CARM1 
haploinsufficient mice in order to understand whether a significant deficiency of CARM1 
could contribute in emphysema development. For this purpose, we firstly assessed the level 
of CARM1 in the lung homoginate from haploinsufficient mice. The mRNA expression data 
by qRT-PCR and the densitometric analysis of western blot displayed that there was a 
significant 40% reduction of CARM1 level at the mRNA (***p<0.001) (Figure 17A) as well as 
at the protein level (**p<0.01) (Figure 17B) in the haploinsufficient mice compared to wild 
type mice (Figure 17B) (please continue to the next page).  
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Figure 17. Reduced CARM1 expression in CARM1 haploinsufficient mice. (A) CARM1 expression at mRNA level 
analyzed by qRT-PCR (B) CARM1 expression at protein level analyzed by western blot and densitometry of the blot, 
**p<0.01, ***p<0.001, student’s t-test, WT vs. CARM1 haploinsufficient animals. WT=Wild type; Het=Heterozygous. Data 
presented are mean ± SD. The experiments were repeated twice (n=4-7). 
 
3.3.2 Elastase treatment enhanced airspace enlargement and lung function impairment 
in CARM1 haploinsufficient mice 
Next, we asked the question whether the haploinsufficient mice responded differently to 
elastase treatment in terms of emphysema susceptibility compared to the wild type mice. To 
answer the question, we measured the mean linear chord length of alveolar airspace by 
NewCAST stereology system from histological sections of mouse lungs of both genotypes. 
The stereological quantification revealed a significant airspace enlargement in CARM1 
haploinsufficient mouse lungs compared to WT animals after elastase treatment (52.5 ± 9.6 
µm vs. 38.8 ± 5.5 µm, **p<0.01) at day 28 (Figure 18A-B). The higher degree of elastase-
induced emphysema was also evident by a significant increase of dynamic lung compliance 
in CARM1 haploinsufficient mice compared to elastase-treated WT mice (2.8 ± 0.32 
µl/cmH20 versus 2.4 ± 0.4 µl/cmH20, *p<0.05) (Figure 18C). PBS-treated WT or CARM1 
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haploinsufficient mice showed no difference in either airspace enlargement (22.28 ± 1.161 
vs. 23.37 ± 0.8792) or lung compliance (0.001374 ± 0.00004710 vs. 0.001391 ± 0.0001266). 
Our data demonstrated for the first time that CARM1 deficiency was capable of predisposing 
mice to a greater susceptibility of emphysema induced by elastase. 
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Figure 18. Augmented emphysema in CARM1 haploinsufficient mice. Mice analyzed on day 28 after elastase induction. 
(A) Representative histological images from H&E stained lung sections. Scale bar: 100 μm. (B) Mean chord length, Lm 
quantified by newCAST. (C) Lung compliance to body weight ratio, *p<0.05, student’s t-test vs. elastase-treated CARM1 
haploinsufficient animals. WT=Wild type; Het=Heterozygous. Data presented are mean ± SD. The experiments were 
repeated twice (n=4-7). 
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3.4 CARM1 Reduction Inducing Senescence in Alveolar Epithelial Cells                      
3.4.1 Loss of anti-senescence SIRT1 in alveolar epithelial cells             
There are several studies reporting that senescence of lung alveolar epithelial cells 
contributes in emphysema development (134, 279). However, the underlying causative 
mechanism remains unsolved. SIRT1, an anti-senescence gene known to defend against 
elastase-induced emphysema via reduction of premature senescence in mice (137). 
Interestingly, CARM1 can regulate SIRT1 activity as CARM1-dependent methylated HuR is 
reported to stabilize SIRT1 transcript (224, 240). Therefore, we investigated whether CARM1 
reduction could contribute in inducing alveolar epithelial cell senescence in emphysematous 
lungs by modulating SIRT1.  
 
Morphological analysis of SIRT1-stained sections (Figure 19A) revealed that elastase 
treatment significantly reduced the percentage of SIRT1 positive alveolar epithelial cells in 
wild type animals which was not further decreased in CARM1 haploinsufficient mice (Figure 
19B). Most importantly, we detected fewer number of SIRT1 positive ATII cells in PBS-
treated CARM1 haploinsufficient mice compared to wild type control mice cells (69.66% ± 
4.55 vs. 56.92 ± 1.99, *p<0.05). This finding proved our speculation correct that CARM1 
deficiency alone could regulate SIRT1 level in ATII. We further confirmed loss of SIRT1 from 
SP-C positive alveolar epithelial cells (ATII) using immunofluorescence co-staining (Figure 
19C). 
We also analyzed SIRT1 in the lung homogenate by western blot and observed a 
downregulation in SIRT1 level in emphysematous lungs (Figure 20A). However, the 
densitometric analysis detected that among control animals, there was a significant decrease 
in SIRT1 level in CARM1 haploinsufficient mice compared to wild type animals (Figure 20A-
B) although elastase treatment did not show further SIRT1 downregulation in 
haploinsufficient mice. One possible explanation could be that the SIRT1 alteration in 
alveolar epithelial cells was masked by other lung cell types expressing SIRT1. 
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Figure 19. (A) Representative images from Immunohistochemistry using antibody against SIRT1 (1:100). Red: positive stain, 
black: negative stain. Scale bar: 20 μm (B) Stereological quantification of SIRT1 positive alveolar epithelial cells by 
newCAST system (C) Representative images from immunofluorescence double staining using antibodies against SIRT1 
(1:100) and ATII-specific marker, SP-C. Green: SP-C positive ATII cells, Red: SIRT1 positive cells, Yellow (merged): SIRT1 
and SP-C double positive ATII cells. Only the region of interest is shown. Scale bar: 10 µm, *p<0.05, **p<0.01, student’s t-
test, wild type vs. CARM1 haploinsufficient mice.  The experiments were repeated twice (n=4-7).  
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Figure 20. (A) Representative western blot for SIRT1 expression at protein level in lung homogenate. β-actin was used as 
loading control (B) Densitometry of the blot, *p<0.05, **p<0.01, student’s t-test, wild type vs. Data presented are mean ± SD. 
The experiments were repeated twice (n=4-7). 
 
3.4.2 Induction of senescence markers in alveolar epithelial cells               
Besides stabilizing SIRT1, CARM1-dependent methylation can also destabilize transcripts of 
p16, which is a hallmark marker for senescence (22, 29, 30). Therefore, we quantified  p16 
stained sections of mouse lungs of wild type and CARM1 haploinsufficient mice (Figure 21A). 
The quantification revealed that elastase-treatment induced an increase in p16 positive 
alveolar epithelial cells in WT as well as in CARM1 haploinsufficient mice. Interestingly, 
control CARM1 haploinsufficient mice showed a significant 2.5 fold increase in basal 
numbers of p16 positive alveolar epithelial cells compared to WT control animals (Figure 
21B).  
In addition, we analyzed protein expression levels of p16 and p21 in lung homogenates by 
western blot (Figure 21C). Elastase treatment increased expression of p16 in CARM1 
haploinsufficient mice although the change was not significant (Figure 21D). For p21, we 
observed that in PBS-treated control animals, CARM1 deficiency alone significantly induced 
the level of p21 in haploinsufficient mice compared to wild type animals (Figure 21C and E).  
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Figure 21. Induction of senescence markers in alveolar epithelial cells (A) Representative lung sections stained with 
anti-p16 Ab (1:50). Scale bar: 20 μm (B) Semi-quantitative manual scoring of p16 positive alveolar epithelial cells (C) 
Representative western blots for p16 (1:200) and p21 (1:200) protein levels in lung homogenate (D) and (E) Densitometric 
analysis of blot for p16 and p21, respectively (E) Representative lung sections stained with antibody against β-galactosidase 
(1:50). Scale bar: 20 μm. Red arrow indicates β- galactosidase positive alveolar epithelial cells, *p<0.05, **p<0.01, student’s 
t-test, WT vs. CARM1 haploinsufficient mice. Data are mean ± SD, experiments were repeated twice (n=4-7).  
  
Next, we analyzed β-galactosidase since it is highly expressed and accumulated in 
senescent cells. We performed immunohistochemistry using antibody against β-
galactosidase and demonstrated that PBS-treated CARM1 deficient mice showed a 
88 
 
considerably higher number of β-galactosidase positive alveolar epithelial cells compared to 
PBS-treated WT animals (Figure 21F). Elastase treatment further increased the number of β-
galactosidase positive cells in CARM1 deficient mice compared to wild type animals.  
 
Taken together, these results thus suggested that CARM1 deficiency attenuated the SIRT1-
regulated anti-senescence mechanism, which therefore induced senescence markers p16, 
p21 and increased β-galactosidase activity in alveolar epithelial cells which ultimately 
accounted for the increased susceptibility of haploinsufficient mice to elastase-induced 
emphysema. 
 
3.5 CARM1 Knockdown in ATII-like Cells Triggering Senescence In Vitro 
3.5.1 CARM1 knockdown in LA-4 cells downregulating SIRT1 expression          
Previously we and others reported that CARM1 is expressed by airway epithelial cells and by 
ATII cells in septal regions (193, 251) (Figure 15A). Based on these reports, we considered 
ATII-like cell line LA-4 to understand the mechanism of CARM1-regulated senescence in 
vitro. With siRNA-mediated gene knockdown technology, we significantly reduced CARM1 
expression by 70% as quantified by densitometric analysis of western blot (Figure 22A upper 
panel, 22B).  
 
Next, we analyzed protein expression of SIRT1 and noticed a significant downregulation in 
siCARM1 transfected cells (*p<0.05) (Figure 22A middle panel, 22C). The finding was 
supported by a significant 1.5 fold reduction of SIRT1 at mRNA level compared to scrambled 
control as analyzed by qRT-PCR (*p<0.05) (Figure 22D) (please continue to the next page). 
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Figure 22. CARM1 reduction cells downregulating SIRT1 in ATII-like cell line LA-4. Cells were transfected with CARM1 
specific siRNA (siCARM1-2 or siCARM1-5) or non-specific scrambled siRNA (Scr) for  48 hours and harvested for 
RNA/protein analysis. Untreated cells were taken as medium control (Co). (A) Representative western blot showing CARM1 
(upper lane) and SIRT1 (middle lane) at protein level. β-actin used as loading control (lower lane). (B) Densitometric analysis 
of the blot for CARM1 (C) Densitometric analysis of the blot for SIRT1, *p<0.05, **p<0.01, student’s t-test, siCARM1-5 vs. Scr 
(D) SIRT1 expression at mRNA level, *p<0.05, 1-way ANOVA. Data as means ± SD. Data were from two independent 
experiments. 
 
3.5.2 Reduced CARM1 inducing senescence markers in LA-4 cells          
We analyzed senescence markers in siCARM1 transfected LA-4 cells and observed a 
significant upregulation of p16 and p21 but not p53 mRNA (Figure 23A-C). Furthermore, 
siCARM1 transfected cells showed a significantly higher percentage of β-galactosidase 
positive cells compared to the scrambled control (50.57% ± 7.364 vs. 2.210% ± 0.3404, 
***p<0.001) (Figure 23D-E). The number of positive cells was comparable to a positive 
control where cells were treated with 100 μM H202 (data not shown).  
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Figure 23. CARM1 reduction accelerated senescence in LA-4. siCARM1 transfected cells were incubated overnight with 
β-galactosidase staining solution. (A-C) mRNA expression of (A) p16, (B) p21 and (C) p53, *p<0.05, **p<0.01, 1-way 
ANOVA. (D) Representative images from β-galactosidase assay. Scale bar: 2 μm (E) Quantification of β-galactosidase 
positive cells from total 300 cells in10 random fields/well in 24-well plate,***p<0.001, 1-way ANOVA. Data were from three 
independent experiments. 
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3.5.3 CSE stimulation augmenting senescence in CARM1 deficient LA-4 cells  
As cigarette smoke is the most common cause of emphysema, we treated LA-4 cells with 
and without 5% cigarette smoke extract (CSE) in combination with siRNA-mediated 
knockdown of CARM1. We observed that CSE induced a reduction of CARM1 expression 
(Figure 24A). Most importantly, in siCARM1-transfected cells stimulated with CSE, the mRNA 
expression level of p21 was significantly upregulated compared to unstimulated siCARM1-
transfected cells (*p<0.05) (Figure 24B).  
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Figure 24. CARM1 reduction accelerated senescence in LA-4. siCARM1-transfected cells were treated with 5% CSE for 
6 hours (A) The mRNA expression level of CARM1 and (B) p21 with or without CSE (C) Representative images of β-
galactosidase assay (D) Quantification of β-galactosidase positive cells. Scale bar: 2 μm, *p<0.05, ***p<0.001, student’s t-
test vs. siCARM1-transfected cells treated with 5% CSE. Data represented as means ± SD. Data were from two independent 
experiments. 
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In accordance with this data, we also observed an elevated β-galactosidase activity in 
siCARM1-transfected cells after CSE stimulation (**p<0.05) (Figure 24C-D) demonstrating 
that senescence in CARM1 deficient cells was further augmented after CSE stimulation.  
These results confirmed that CARM1 reduction triggered an accelerated senescence in LA-4 
cells.   
 
3.6 Reduced CARM1 Hindering Regeneration and Trans-differentiation of 
ATII Cells 
3.6.1 Reduced CARM1 impairing wound healing 
Given that the reduction of CARM1 induced senescence in ATII cells, we sought to 
determine the impact of CARM1 on alveolar epithelial cell function and repair capacity. We 
designed a wound-healing assay using siCARM1-transfected LA-4 cells where the cell 
monolayer was scratched to induce a wound. CARM1-deficient cells exhibited a significant 
decrease in proliferation and migratory distance as evidenced by a 72.7% ± 12.2 
(***p<0.001) reduction in gap closure compared with scrambled siRNA (Figure 25A-B).  
 
This finding suggested that reduced CARM1 led to impaired wound healing of ATII-like cells. 
However, we did not observe any downregulation in the expression levels of proliferation 
markers such as PCNA, Cyclin E1 or ki67 in CARM1 deficient LA-4 cells (Figure 25C-E) 
(please continue to the next page). 
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Figure 25. CARM1 reduction impaired wound healing in LA-4 cells. (A) Wound healing assay performed in confluent 
cultures of siCARM1-5 transfected LA-4 cells using a pipette tip. Scale bar: 200 μm. (B) Quantification of gap closure 
determined 16 hours after injury (C) mRNA expression of PCNA, (D) Cyclin E1, (E) ki67, ***p<0.001, 1-ANOVA. Data from 
three independent experiments. 
 
3.6.2 CARM1 reduction inducing aberrant ATII trans-differentiation            
In vivo repair mechanisms consist of cellular regeneration, migration and differentiation. 
CARM1 is previously reported to regulate the differentiation of ATII into ATI cells, in the 
embryonic E18.5 mouse lung (251). We explored the role of CARM1 in the differentiation of 
adult murine cells by culturing primary ATII cells from WT animals, for 5 days under 
appropriate conditions.  
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Figure 26. CARM1 reduction impaired trans-differentiation of alveolar epithelial cells. (A) CARM1 mRNA expression 
during differentiation of isolated primary ATII cells into an ATI-like phenotype in culture at indicated days, *p<0.05, 1-way 
ANOVA, Dunnett's multiple comparison test vs. d1, n=3 (B) Representative western blot for protein levels of CARM1 and T1α 
at indicated days of culture of isolated primary ATII cells from WT and CARM1 haploinsufficient animals (C) and (D) 
Densitometric analyses of western blots for CARM1 and T1α, respectively, the data are normalized to day 1, *p<0.05, 
student’s t-test vs. CARM1 haploinsufficient mice. Data represented as means ± SD. Data from two independent 
experiments.  
 
From day 3, isolated ATII cells from WT animals started to differentiate into ATI-like cells as 
demonstrated by expression of the ATI cell marker expression T1alpha. During ATII to ATI 
cell trans-differentiation CARM1 was significantly upregulated as analyzed by qRT-PCR 
(Figure 26A).  
 
Similarly, we also isolated and cultured primary ATII cells from CARM1 haploinsufficient 
mice. We detected a significant  downreguation of T1α at protein level at day 5 in these mice 
compared to WT mice indicating that CARM1 deficiency might lead to impaired differentiation 
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(Figure 26B-D). This indicates that CARM1 expression is associated with alveolar epithelial 
cell trans-differentiation processes. Finally, we analyzed the number of SP-C positive cells in 
emphysematous mouse lungs. We observed an increased ratio of SP-C positive cells to the 
total cell nuclei in elastase-treated CARM1 haploinsufficient mice compared to PBS-treated 
haploinsufficient mice (Figure 27A-B) suggesting that the higher number of ATII cells 
probably resulted from impaired trans-differentiation.   
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Figure 27. CARM1 reduction accumulated SP-C positive ATII cell in mouse lungs. (A) Representative 
immunofluorescence images showing SP-C (green) positive alveolar epithelial cells on lung sections from WT or CARM1 
haploinsufficient mice treated with either PBS or elastase. DAPI (blue) used as nuclear staining. Scale bar: 50 μm (B) 
Stereological quantification of SP-C positive alveolar epithelial cells to total number of nuclei, **p<0.01, 1-way ANOVA, PBS 
vs. elastase-treated CARM1 haploinsufficient animals. Data represented as means ± SD. Data from two independent 
experiments. 
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4. DISCUSSION  
 
Emphysema is characterized by enlargement of alveolar spaces accompanied with 
destruction of alveolar walls in the absence of any obvious fibrosis (6). The progressive and 
irreversible alveolar destruction results in reduced elastic recoiling and decreasing alveolar 
capillary exchange area (280). Cigarette smoking is by far the most common cause of 
pulmonary emphysema. In the lower respiratory tract of the lungs cigarette smoke induces 
an inflammatory response by recruiting alveolar macrophages and neutrophils (6). The 
activated inflammatory cells release an array of proteases, oxidants and toxic peptides and 
trigger damage to the lung structures by apoptosis, oxidative stress, and protease/anti-
protease imbalance and premature aging/senescence of lung cells. Taken together, these 
are believed to be the major causes of the tissue destruction by which emphysema is 
defined.  
 
Aging is considered as a major risk factor for chronic obstructive pulmonary disease (COPD) 
(284). It was recently thought that cigarette smoke (CS) and noxious gases trigger 
accelerated premature aging of the lung via cellular senescence (63, 121). There are 
evidence demonstrating that cellular senescence of different types of lung cells is 
accelerated in COPD patients and these cell types include alveolar type II cells, endothelial 
cells, fibroblasts, and peripheral blood lymphocytes (124, 126, 285, 286). Aging/senescence 
is a stress response marked by a progressive decline in the function of multiple cells and 
tissues in lungs (287). Recently, the lungs of smokers with emphysema were associated with 
overexpression of the cellular senescence marker p16 and telomere shortening in both 
alveolar epithelial type II (ATII) and endothelial cells (126). Deficiency in the anti-senescence 
protein (SMP30) in mice also promotes airspace enlargement after cigarette smoke exposure 
(288). Cellular senescence is a state of irreversible growth arrest. Senescent cells are 
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presumed to contribute to the pathogenesis of age-related diseases by inhibiting tissue 
repair, because these cells are viable yet unable to divide and to repair tissue defects (121, 
125, 289-291). Therefore, our study aimed at investigating the role of coactivator-associated 
arginine methyltransferase (CARM1), a PRMT family member regulating cellular senescence 
via the anti-aging protein/histone deacetylase SIRT1, in elastase-induced emphysema in wild 
type and CARM1 haploinsufficient mice. We reported for the first time that CARM1 deficiency 
caused enhanced emphysema by accelerating senescence via SIRT1 leading to impaired 
regeneration and differentiation of alveolar epithelial cells. 
 
In order to mimic the irreversible structural changes occurring in the lungs of COPD patients 
even after smoking cessation (147), the elastase-induced emphysema mouse model is a 
useful and well-established model. Despite its known half-life of a few hours and a turn-over 
rate of 99% in four days (145, 146), elastase triggers a continuous airspace enlargement and 
lung function decline even after stimulus cessation (139, 140). We used the porcine 
pancreatic elastase (PPE)-induced emphysema model as an alternative to the cigarette 
smoke (CS) model. PPE degrades extracellular matrix components like elastin, collagen and 
fibronectin. Natural sources of elastases in the lung are neutrophils and macrophages (73). 
This model can be established by a single treatment inducing progressive emphysema 
development that can reliably be monitored by lung function tests (140). Protease-induced 
emphysema is probably the most commonly used emphysema model, since it is easy to 
establish and reproducible, and the pathological changes develop quickly (292). Studies 
showed that hamsters or mice treated with PPE develop emphysema within a few days 
(277). This disease model is therefore very feasible to induce concentration dependent 
emphysema (139). In contrast cigarette smoke model takes considerably more time to 
induce significant pathological changes in the lung (starting from 4 months of exposure) 
(155). Furthermore, CS exposure of animals for up to 6 months only produces a mild 
disease, probably equivalent to human Global Initiative on Chronic Obstructive Lung Disease 
98 
 
(GOLD) stage 1 or 2 (293). Although elastase model and cigarette smoke model both 
demonstrate pathologically relevant emphysematous changes, the differences in injury 
pathway is still not completely known. Furthermore, the onset and duration of lesions differ in 
both models. To complement our elastase model, we performed an in vitro study with 
cigarette smoke extract (CSE) on siCARM1-treated LA-4 cells to evaluate the effect of CSE 
on cells with reduced CARM1. In addition, for a future study, we plan to use CS model on 
SP-C-cre CARM1 mice.  
 
In our current study, we monitored elastase-induced emphysema progression in wild type 
mice for a period of 161 days. The first evidence of emphysema development was indicated 
by the impaired pulmonary function two days after elastase application. Further decline was 
followed till day 161. We demonstrated a significant increase of airspace enlargement in 
response to elastase treatment, which strongly correlated with increased dynamic lung 
compliance. Additionally, we found a decreasing Tiffeneau index (FEV0.1/FVC ratio), along 
with emphysema progression, which is an important characteristic for COPD patients. Most 
recently, a study monitored and described emphysema progression for 12 weeks by using 
morphometry and micro-computed X-ray tomography (148). In contrast, in our study, lung 
function tests reliably monitored emphysema progression until 161 days proving these as 
useful diagnostic tools.  
 
Inflammatory cells were detectable in bronchoalveolar lavage (BAL) fluid after elastase 
treatment only during the first four weeks which afterwards resumed to normal levels. As 
expected, the first early inflammatory responses were neutrophils, which are first recruited to 
the injured site and release neutrophil elastase, an important emphysema-related enzyme 
(292). Furthermore, we observed a significant accumulation of macrophages in BAL fluid 
until day 28, which are known to release macrophage elastase e.g. MMP12, thereby further 
contributing to emphysema development in addition to elastase-induction (294). This 
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observation is important because the later time points (day 56 and 161) provided the 
opportunity to study inflammation-independent progressive emphysema mechanisms, 
comparable to the situation of reduced inflammation but progressive emphysema after 
cigarette smoke cessation (295, 296).  
 
Besides regulating senescence, CARM1 was shown to be indispensable for normal lung 
development, specifically for alveolar proliferation and differentiation. Using electron 
microscopy, it was observed that the ATII cells in the lungs of the CARM1 homozygot  mice 
did not differentiate normally into alveolar type I (AT1) cells. In addition, many cell-cycle 
genes and markers of AT1 differentiation was dysregulated in CARM1 homozygot mouse 
embryos (232, 251). Interestingly, CARM1 was downregulated in ATII cells of 
emphysematous lungs starting from day 28.  
 
Although we did not observe any change in global level of CARM1 protein expression in lung 
homogenates among different time points analyzed by western blot but there was a change 
in the level of phosphorylated CARM1 at day 161. Phosphorylation of CARM1 at a conserved 
serine residue (Ser-228 in human and Ser-229 in mouse) is known to prevent CARM1 
binding with the methyl donor S-adenosylmethionine (AdoMet) thus inhibit its enzymatic 
activity (244, 245). Phosphorylation at Ser-217 also acts as a molecular switch for controlling 
CARM1 enzymatic activity during the cell cycle (244, 245). The significant increase in the 
ratio of phospho-CARM1 to CARM1 level that we observed as a late effect on CARM1 
phosphorylation indicated a reduced CARM1 activity after elastase treatment. Most 
importantly, we demonstrated that CARM1 deficiency leading to pronounced and accelerated 
emphysema progression at day 28 in response to elastase treatment proving its crucial role 
in lung architecture maintenance.  
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Remarkably, CARM1 is reported to be downregulated in testis, thymus and heart of 24-
month old aging rats (264). CARM1 reduction is also observed in replicative and H2O2-
induced premature senescence of human diploid fibroblasts (263). Based on these reports 
and our initial findings, we hypothesized that diminished CARM1 levels might promote 
enhanced emphysema by regulating cellular senescence. Therefore, we investigated SIRT1, 
an NAD+-dependent lysine deacetylase functioning in multiple cellular events but most 
importantly in control of lifespan and thus acting as an anti-senescence gene (242). In the 
lungs of smokers or COPD patients, SIRT1 is reported to be downregulated (136, 297). In 
mice, SIRT1 deficiency led to enhanced emphysema in both an elastase- and cigarette 
smoke-induced models (137).  
 
Indeed, we observed a reduced basal level of SIRT1-positive alveolar epithelial type II cells 
in CARM1 deficient mice. CARM1 is reported to stabilize SIRT1 transcripts by CARM1-
dependent methylation of HuR (240). We presumed that this intrinsic pro-senescent status of 
alveolar epithelial cells observed in our study resulted from decreased stabilization of SIRT1. 
However, as there was no significant change in the levels of SIRT1 after elastase treatment 
in CARM1 haploinsufficient mice, we speculate that further reduction after elastase treatment 
was masked by other lung cells, especially by airway cells, fibroblasts, endothelial cells and 
monocytes/macrophages which also express SIRT1 (136, 137, 298, 299). Nevertheless, our 
in vitro study showing SIRT1 downregulation after siRNA-mediated CARM1 knockdown in 
LA-4 cells further confirmed the presence of a CARM1-SIRT1 axis in regulation of 
senescence, particularly in ATII cells.  
 
These results were corroborated by an increased basal level of p16 positive alveolar 
epithelial cells in CARM1 deficient mice and significant upregulation of p16 as well as p21 in 
CARM1 deficient LA-4 cells. In addition, the global protein levels determined by western blot 
also revealed that CARM1 deficiency alone significantly induced the protein level of p16 and 
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p21 in haploinsufficient mice compared to wild type animals. These cyclin-dependent kinase 
(CDK) inhibitors are two of the widely used senescence markers known to increase with 
cellular senescence in several rodent and human tissues and most importantly in alveolar 
epithelial cells of COPD patients (126, 133, 300). Moreover, previous studies showed 
CARM1-dependent post-translational methylation of HuR enhancing its association with p16 
or p21 mRNA and leading to transcript degradation, whereas absence of CARM1 led to 
transcript stabilization (224, 239, 301).  
 
Another hallmark senescence marker is p53 (302) but in CARM1 homozygot mouse lungs, 
p53 is downregulated, demonstrating that CARM1 serves as a coactivator for p53 
transcription (251).  Despite the contradictory, we analyzed p53 expression by qRT-PCR but 
not significant difference was found between siCARM1 and scramble siRNA transfected 
cells. As an underlying reason, we speculate that p53 stabilization and activity is regulated by 
other pathways rather than CARM1-dependent methylation. Another explanation is that the 
downregulated transactivation of p53 by coactivator function of CARM1 that O'Brien et al., 
observed is cell type-scpecific and does not occur in ATII cells.   
 
Besides cyclin-dependent kinase (CDK) inhibitors, another known characteristic of senescent 
cells is an elevated β-galactosidase activity at pH 6 which is usually absent in pre-senescent, 
quiescent or immortal cells (305). The impact of CARM1-mediated regulation on senescence 
was confirmed by increased numbers of β-galactosidase positive alveolar epithelial cells in 
siCARM1-treated cells which was further augmented after CSE stimulation demonstrating 
that CARM1 deficiency could further enhance the senescence induction following injury 
stimulus in ATII cells. Similarly, CARM1 deficiency was capable of inducing senescence in 
alveolar epithelial cells in mouse lungs which was considerably increased after elastase 
treatment and thus proved importance of CARM1 to regulate cellular senescence. The 
impact of CARM1-mediated regulation on senescence was confirmed by increased numbers 
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of senescence-associated β-galactosidase (SA-β-gal) positive LA-4 cells after siCARM1 
transfection.  
 
Exposures to cigarette smoke are reported to turn lung alveolar epithelial cells, fibroblasts 
and airway cells into an irreversible state of senescence (127, 306, 307). This results in an 
inability to repair lung injury which is a characteristic feature of emphysema.  For our in vitro 
study, we used cigarette smoke extract (CSE) in combination with siRNA-mediated 
knockdown of CARM1 in LA-4 cells with twofold purposes. Firstly, to probe its impact on 
CARM1 expression and secondly, to investigate whether CSE could further augment 
senescence in CARM1 deficient cells. We used 5% CSE and treated the cells for 6 hours in 
this experiment, because we have found earlier that this CSE concentration does not induce 
cell death (unpublished observation). We indeed observed CSE-mediated reduction of 
CARM1 expression although there were no changes in gene expression for p16, p53 and 
SIRT1 (data not shown). In contrast, p21 levels as well as SA-β-gal activity were elevated in 
siCARM1-transfected cells after CSE stimulation. These results demonstrated that reduced 
CARM1-induced senescence was further enhanced after CSE stimulation.   
 
CARM1-deficient mice are reported to demonstrate  hyper-proliferative immature ATII cells 
that  are incapable of trans-differentiating into ATI cells (251). Contrary to the report, we 
observed a reduced gap closure in CARM1 knockdown LA-4 cells. Our finding suggested 
that CARM1 was necessary for wound healing after an occurance of an induced injury. This 
indicated that CARM1 deficiency delayed the cellular repair mechanism in the lung and 
impaired repair capacity is a prominent feature of emphysematous lungs.  
 
As proliferation and migration are two principle phases of wound healing, we also considered 
analyzing proliferation markers, such as PCNA, Ki67 and CyclinE1 by qRT-PCR. However, 
we did not observe any downregulation in proliferation in CARM1 deficient LA-4 cells. We 
103 
 
would like to point out here that we quantified the gap closure after 16 hours of introducing 
the wound. One explanation could be that the proliferative phase might have been impaired 
at an earlier time point in CARM1 deficient cells which resumed to normal level by 16 hour 
and that were why we did not observe any change in the expression levels of proliferation 
markers. A time course following wound induction would perhaps provide further information 
on changes in proliferation in siCARM1-treated cells.  
 
CARM1 has been implicated in differentiation of chondrocytes, myoctes, T cell, human 
embryonic stem cell and most important alveolar epithelial type II (ATII) cells (204, 240, 250, 
251, 261). In accordance with these reports, we also observed an upregulation of CARM1 
during trans-differentiation of isolated murine ATII cells into AT1 cells in culture conditions 
suggesting a direct association of CARM1 in differentiation process. Additionally, we 
demonstrated that alveolar epithelial senescence resulting from reduced CARM1 could also 
impair trans-differentiation of ATII cells into ATI cells as manifested by a significant 
downreguation of T1α at protein level in cultured ATII cells isolated from CARM1 deficient 
mice compared to wild type animals on day 3 and 5 when the differentiation process starts to 
occur.  
 
O’Brien et al. reported hyperproliferation of pro SP-C positive cell in CARM1 deficient mouse 
lungs. In our study, we showed that elastase-treatment acts as a trigger in CARM1 deficient 
mouse lungs to stimulate ATII cells hyperproliferation. We speculate that the increase in 
ProSPC positive cells could be an outcome of dysregulated trans-differentiation of ATII into 
ATI thereby leading to an accumulation of ATII cells. Wnt signaling pathway might act as an 
underlying mechanism. It is possible that CARM1 regulates trans-differentiation of ATII cells 
via the WNT signaling pathway involved in alveolar epithelial trans-differentiation (308). 
Activation of Wnt/β-catenin signaling during lung injury promotes alveolar epithelial 
differentiation toward an ATI-like phenotype (309) and recently, downregulation of WNT/β-
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catenin signaling has been implicated in parenchymal tissue destruction and impaired repair 
capacity in lungs of COPD patients (62). The methyltransferase domain of CARM1 can 
specifically interact with β-catenin and thus acts as a bona fide coactivator for Wnt/β-catenin 
signaling (257) indicating that CARM1-regulated Wnt pathway might be involved in alveolar 
epithelial differentiation. However, further study is required to elaborate how CARM1-
regulated senescence could lead to impairment of alveolar epithelial trans-differentiation 
during emphysema development. Especially the upstream pathways regulating CARM1 via 
post-translational modifications might be a promising target for future investigation.  
 
Collectively, our data support the senescence hypothesis of emphysema development in 
COPD. Our study demonstrate that indeed the cellular senescence contributed to the 
pathogenesis of emphysema and this is mediated via a CARM1-SIRT1-axis in ATII cells. We 
identified CARM1 as the upstream regulator of SIRT1 governing  senescence and 
modulating regeneration, repair and differentiation of ATII to AT1 cells. Most importantly, 
from a therapeutic approach, our  findings also provide an alternative strategy to treat 
emphysema. As there is no current treatment to reverse the alveolar destruction that is 
continuously occurring in emphysematous lung, therefore, arresting or slowing down the 
disease progression is a more realistic goal to achieve. Pharmacological intervention such as 
targeted drugs or inhibitors might be an effective as well as practical approach to induce 
CARM1 or to prevent its degradation, respectively in patient with emphysema. Thus, CARM1 
may prove to be an effective target to  decelerate the premature lung aging process 
observed in COPD patients. 
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6. ABBREVIATION 
 
AP  Alkaline phosphatase 
ATCC American type culture collection 
AAT Alpha1-antitrypsin 
ATI Alveolar epithelial type I 
ATII Alveolar epithelial type I 
ANOVA  One-way analysis of variance 
BAL Bronchoalveolar lavage 
cDNA  Complementary DNA 
COPD  Chronic obstructive pulmonary disease 
Ct  Cycle threshold 
CAST Computer assisted stereological toolbox 
CARM1 Co-activator associated arginine methyltransferase 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleotide triphosphates mix 
ELISA  Enzyme-linked immunosorbent assay 
HPRT1 hypoxanthine phosphoribosyltransferase 1 
PBS Phosphate buffered saline 
kDa  Kilo Dalton 
L(p)  Length per point 
MCL  Mean chord length 
MMPs  Matrix metalloproteinases 
mRNA  Messenger RNA 
PFA  Paraformaldehyde 
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PCR  Polymerase chain reaction 
pH  Potential of hydrogen 
PPE  Porcine pancreatic elastase 
PVDF  Polyvinylidene fluoride 
WT Wild type 
Het Heterozygous 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RT  Reverse transcription 
Rtase  Reverse transcriptase 
SDS  Sodium dodecylsulfate 
SP-C  Surfactant protein-C 
WHO  World Health Organization 
SIRT1 Sirtuin1 (silent mating type information regulation 2 homolog 1)  
DAPI 4',6-diamidino-2-phenylindole 
ΔCt  Delta cycle threshold 
μg  Microgram 
μl  Microlitre 
μm  Micrometer 
DMF Dimethylformamide 
HIER Heat Induced Epitope Retrieval 
NEA Non-essential amino acids  
VFR Vulcan fast red  
RIPA Radioimmunoprecipitation assay  
TBS   Tris-buffered saline  
MEF Mouse embryonic fibroblast  
DMEM Dulbecco's Modified Eagle's Medium 
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RPMI medium Roswell Park Memorial Institute medium 
FBS Fetal bovine serum 
BSA Bovine serum albumin 
siRNA Small interfering RNA 
PCNA Proliferating cell nuclear antigen 
Cyc E1 Cyclin E1 
FVC Forced Expiratory Volume 
FRC Functional Residual Capacity 
TLC Total Lung Capacity  
Cdyn Dynamic compliance  
BW Body weight 
E Elastance 
H&E Hematoxylin and eosin  
NTC Non template control  
BCA assay Bicinchoninic acid assay  
HRP Horseradish peroxidase  
CSE Cigarette smoke extract  
AdoMet S-adenosyl-L-methionine  
ADMA Asymmetric ω-NG, NG-dimethylarginine  
PRMT Protein arginine methyltransferases  
GAR  Glycine- and arginine-  
PGM  Proline-, glycine-, methionine-  
MMA ω-NG-monomethyl arginine  
SDMA symmetric ω-NG, N′G-dimethylarginine  
NOS Nitric oxide synthase  
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